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Abstract: Neuropathic pain (NP) is an increasingly common chronic pain state and a major
health burden, affecting approximately 7-10% of the general population. Emerging
evidence suggests that genetic factors could partially explain individual susceptibility to
NP and the estimated heritability in twins is 37%. The aim of this study was to
systematically review and summarize the studies in humans that have investigated the
influence of genetic factors associated with NP. We conducted a comprehensive
literature search and performed meta-analyses of all the potential genetic variants
associated with NP. We reviewed 29 full-text articles and identified 28 genes that were
significantly associated with NP, mainly involved in neurotransmission, immune
response, and metabolism. Genetic variants in HLA genes, COMT, OPRM1, TNFA,
IL6, and GCH1, were found to have an association with NP in more than one study. In
the meta-analysis, polymorphisms in HLA-DRB1*13 (OR,2.96; CI,1.93-4.56), HLA-
DRB1*04 (OR,1.40; CI, 1.02-1.93), HLA-DQB1*03 (OR,2.86; CI,1.57-5.21), HLA-A*33
(OR,2.32; CI,1.42-3.80), and HLA-B*44 (OR,3.17; CI,2.22-4.55) were associated with
significantly increased risk of developing NP whereas HLA-A*02 (OR,0.64; CI,0.47-
0.87) conferred reduced risk and neither rs1799971 in OPRM1 (OR, 0.55; CI, 0.27-
1.11) nor rs4680 in COMT (OR, 0.95; CI, 0.81-1.13) were significantly associated with
NP. These findings demonstrate an important and specific contribution of genetic
factors to the risk of developing NP. However, large-scale replication studies are
required to validate these candidate genes. Our review also highlights the need for
genome-wide association studies with consistent case definition to elucidate the
genetic architecture underpinning NP.
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Abstract  
Neuropathic pain (NP) is an increasingly common chronic pain state and a major health burden, 
affecting approximately 7-10% of the general population. Emerging evidence suggests that genetic 
factors could partially explain individual susceptibility to NP and the estimated heritability in twins 
is 37%. The aim of this study was to systematically review and summarize the studies in humans 
that have investigated the influence of genetic factors associated with NP. We conducted a 
comprehensive literature search and performed meta-analyses of all the potential genetic variants 
associated with NP. We reviewed 29 full-text articles and identified 28 genes that were 
significantly associated with NP, mainly involved in neurotransmission, immune response, and 
metabolism. Genetic variants in HLA genes, COMT, OPRM1, TNFA, IL6, and GCH1, were found 
to have an association with NP in more than one study. In the meta-analysis, polymorphisms in 
HLA-DRB1*13 (OR,2.96; CI,1.93-4.56), HLA-DRB1*04 (OR,1.40; CI, 1.02-1.93), HLA-
DQB1*03 (OR,2.86; CI,1.57-5.21), HLA-A*33 (OR,2.32; CI,1.42-3.80), and HLA-B*44 (OR,3.17; 
CI,2.22-4.55) were associated with significantly increased risk of developing NP whereas HLA-
A*02 (OR,0.64; CI,0.47-0.87) conferred reduced risk and neither rs1799971 in OPRM1 (OR, 0.55; 
CI, 0.27-1.11) nor rs4680 in COMT (OR, 0.95; CI, 0.81-1.13) were significantly associated with 
NP. These findings demonstrate an important and specific contribution of genetic factors to the 
risk of developing NP. However, large-scale replication studies are required to validate these 
candidate genes. Our review also highlights the need for genome-wide association studies with 
consistent case definition to elucidate the genetic architecture underpinning NP. 
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A systematic review and meta-analysis of genetic risk factors for neuropathic 
pain 
Abstract  
Neuropathic pain (NP) is an increasingly common chronic pain state and a major health burden, 
affecting approximately 7-10% of the general population. Emerging evidence suggests that genetic 
factors could partially explain individual susceptibility to NP and the estimated heritability in twins 
is 37%. The aim of this study was to systematically review and summarize the studies in humans 
that have investigated the influence of genetic factors associated with NP. We conducted a 
comprehensive literature search and performed meta-analyses of all the potential genetic variants 
associated with NP. We reviewed 29 full-text articles and identified 28 genes that were 
significantly associated with NP, mainly involved in neurotransmission, immune response, and 
metabolism. Genetic variants in HLA genes, COMT, OPRM1, TNFA, IL6, and GCH1, were found 
to have an association with NP in more than one study. In the meta-analysis, polymorphisms in 
HLA-DRB1*13 (OR,2.96; CI,1.93-4.56), HLA-DRB1*04 (OR,1.40; CI, 1.02-1.93), HLA-
DQB1*03 (OR,2.86; CI,1.57-5.21), HLA-A*33 (OR,2.32; CI,1.42-3.80), and HLA-B*44 (OR,3.17; 
CI,2.22-4.55) were associated with significantly increased risk of developing NP whereas HLA-
A*02 (OR,0.64; CI,0.47-0.87) conferred reduced risk and neither rs1799971 in OPRM1 (OR, 0.55; 
CI, 0.27-1.11) nor rs4680 in COMT (OR, 0.95; CI, 0.81-1.13) were significantly associated with 
NP. These findings demonstrate an important and specific contribution of genetic factors to the 
risk of developing NP. However, large-scale replication studies are required to validate these 
candidate genes. Our review also highlights the need for genome-wide association studies with 
consistent case definition to elucidate the genetic architecture underpinning NP. 
Keywords 
Neuropathic pain, Genetic risk factor, Polymorphisms, Genome-wide association studies, 
Candidate gene association studies, Systematic review, Meta-analysis. 
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Introduction 
Neuropathic pain (NP) is an increasingly common chronic pain state, arising as a result of a lesion 
or disease affecting the somatosensory system [48,68]. NP is a complex condition with distinct 
symptoms and has a great impact on health-related quality of life, sleep, mood and anxiety [15,60]. 
NP affects approximately 7-10% of the general population [4,27], 20-26.4% of individuals with 
diabetes [5,11], and 10-20% of individuals following herpes zoster in the UK [24,37,76]. Up to 
37% of individuals with low back pain [22,54] and 40% of people after surgery [36] suffer from 
NP. Studies have found  that NP affects approximately 8.1 and 17.9% of the Canadian population 
[67,70]. Inoue et al reported that the prevalence of NP is lower (3.2%) in the East Asian population 
[34].  
Genetic susceptibility, as well as environmental factors such as sociodemographic, psychological, 
clinical, and lifestyle factors, are known to contribute to the risk of developing NP [21,26,41]. 
Evidence from human genetic studies have shown that some rare NP disorders including 
congenital sensitivity to pain with anhidrosis, erythromelalgia, and paroxysmal extreme pain 
disorder are monogenic, caused by mutations in a single gene, SCN9A [14,17,33,77]. It has been 
proposed that the contribution of multiple genes can help to understand why some individuals are 
susceptible to chronic NP after nerve injury or disease while others are not. Initially, several animal 
model studies established that NP is partially heritable [12,13] and show the existence of gene-
environment interactions in NP susceptibility. Recently, a twins study from the UK reported an 
estimated heritability of NP of 37% [50] suggesting that genetic factors have the potential to 
determine a significant proportion of an individual’s predisposition to NP. A recent genome-wide 
associated study (GWAS) also found that NP had a heritable component (11%) in a diabetic 
population [47]. Several genetic association studies have found variants associated with the risk of 
developing NP in different conditions as well as affecting pain severity. However, the underlying 
genetic mechanisms contributing to NP remain elusive due to inconsistent results and lack of 
validation in the current evidence.  
Identifying genetic factors for NP and summarising the results from all studies to date will help to 
confirm known potential genetic risk variants underlying NP which may provide useful biomarkers 
for clinical prognosis and pharmacological targets. We therefore performed a comprehensive 
literature-based systematic review to identify studies of genetic risk factors of NP in humans. This 
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will help to determine the level of evidence by performing a meta-analysis of each gene association 
with NP and to explore the functional annotation of identified genetic variants.  
Methods 
Search strategy 
The systematic review protocol was registered in the international prospective register of 
systematic reviews (PROSPERO registration number CRD42016043523) [71]. Literature searches 
and meta-analysis were conducted and reported according to the Preferred Reporting Items of 
Systematic reviews and Meta-analyses (PRISMA) guidelines [49]. We conducted a 
comprehensive literature search limited to human studies using electronic databases including 
PubMed, MEDLINE, EMBASE, SCOPUS and Web of Science from January 1996 to July 2016. 
This was based on a previous systematic review search strategy [28]  and we validated the search 
terms using the pre-selected articles. The search terms used for all five databases included terms 
related to neuropathic pain, genetic factors and study design. These keywords were combined 
using Boolean operators (see Supplementary Table S1). The Human pain gene database 
(http://hpgl.ca/hpgdb/) was searched for any additional studies using the following keywords: 
neuropathic, post-operative, diabetic, sciatica, and multiple sclerosis.  
Study criteria 
All genetic studies including molecular genetics findings, candidate gene association studies 
(CGAS), and GWAS focussing on genetic factors influencing the risk of developing NP in adult 
patients, were considered for inclusion. Only English language articles were considered. We 
excluded review articles, case reports, and genetic studies exclusively on animal models. We 
omitted studies only on genetic determinants for neuropathic pain severity as well as genetic 
studies on cancer pain and non-neuropathic pain. Inclusion and exclusion criteria are listed in 
Supplementary Table S2. 
Data collection 
The first author (AV) performed literature searches and removed the duplicates identified in all 
five databases. Articles were screened using the keywords in titles and abstracts using R [65] script 
and verified manually to determine whether they met the above study criteria. Articles were 
examined and assessed independently by AV and the second author (HLH). Further, reference lists 
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of all screened articles were used to retrieve additional studies by hand search. Subsequently, full-
text articles were retrieved and reviewed for eligibility. Any disagreements were discussed 
between AV and HLH. The list of excluded studies after full-text screening can be found in 
Supplementary Table S3. Twenty-seven articles were included from preliminary searches and then 
we re-ran the searches in April 2017 using the original search strategies to include any more recent 
studies.  
Data extraction 
Data extraction was performed by the first author and any clarification was discussed with last 
author (BHS). The quality of all included studies was evaluated according to the Strengthening the 
Reporting of Genetic Association study (STREGA) guidelines [43]. The quality score was 
calculated for each study based on the 22 key items grouped into seven categories: title and 
abstract, background, study selection, statistical methods, reporting outcome, statistical methods, 
previous supporting evidence or validation, and funding source information (see Supplementary 
Table S4, S5) and scores ranged from 0 (lowest) to 30 (highest). Higher scores represent higher-
quality studies. The following information was extracted from all the included studies: first author, 
year, study type, study characteristics, genotype method, genes, genetic markers, allele 
frequencies, statistical model and outcomes. Information on the transcriptional and epigenetic 
regulation of single nucleotide polymorphisms (SNP) were obtained using the RegulomeDB [6], 
UCSC genome browser [61], and Haploreg [74]. 
Meta-analysis 
We conducted meta-analyses of all the potential risk variants that were reported by more than one 
study on different NP conditions. We calculated odds ratios (OR) and 95% confidence intervals 
(CIs) using reported allele frequencies by authors. We performed fixed effect meta-analyses to 
determine the summary risk estimates and CIs, and assessed the heterogeneity across the studies 
by calculating I2, and heterogeneity p-value from Cochrane Q test and generated forest plots using 
metafor R –package [72]. Publication bias was assessed using Egger’s regression test for 
asymmetry and funnel plots were generated using metafor R-package [72]. 
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Results 
Study selection 
The systematic literature searches resulted in 3461 studies after removing duplicates and non-
English language articles. We did not find any additional studies through other resources. After 
screening titles and abstracts, 48 relevant full-text articles were assessed, of which 21 articles that 
did not meet the study criteria were excluded as they were treatment response studies, studies 
investigating genetic predictors for NP severity, or studies investigating pain-related conditions 
that are not considered to be NP. Figure 1 illustrates the study selection process and reasons for 
full-text articles exclusion. Two studies [8,75] were identified when we updated the systematic 
search until April 2017. We therefore identified a total of 29 studies for inclusion in this review 
published between January 1999 and April 2017. 
Characteristics of included studies 
The characteristics of the study type, sample size, case-control ascertainment and study population 
are summarized in Table 1. Of the 29 studies, 21 were CGAS, 4 employed traditional molecular 
genetic methods, and 3 used GWAS on different NP conditions. The most studied NP conditions 
were persistent post-surgical pain (PPSP), diabetic neuropathic pain (PDPN), post-herpetic 
neuralgia (PHN), and sciatica. Other NP conditions, including carpal tunnel syndrome (CTS), 
trigeminal neuralgia (TN), and pain in multiple sclerosis (MS) patients were studied at least once 
(see Figure 2). Seventeen studies investigated NP risk in a European population, seven studies 
were based in an East Asian population, two studies were conducted in an American population 
with ad-mixed ancestry, and other studies were conducted in Israeli and South African populations. 
Most of the studies had a very small sample size (< 500 samples). NP case ascertainment varied 
across the studies: 24 studies screened the subjects based on clinical examination and/or used an 
assessment tool and questionnaires for pain (MRI, quantitative sensory testing, and monofilament 
test), 2 studies used only questionnaires (Inguinal pain, painDETECT) and 2 studies from the same 
cohort used a prescription history and/or clinical assessment tool. In all studies, either healthy 
subjects with no history of pain, or patients affected by disease of interest who did not develop 
neuropathic pain, were defined as controls. All included studies mainly focussed on the influence 
of genetic variants in the risk of developing NP and a very small number of studies examined the 
genetic factors for NP severity as well. Table 2 presents the summary of genetic markers, genotype 
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method, and statistical modelling used in all 29 studies, study outcomes, risk alleles identified, 
information on HWE, effect-sizes, CIs, and p-values, if they were provided by the authors. The 
calculated quality score for all genetic association studies is shown in Table 2. The accuracy and 
transparency of reporting study outcomes improved from earlier studies to most recent studies (see 
Supplementary Figure S1).  
Molecular genetics studies 
Molecular genetics studies identified an association between NP and variants in three genes 
(SCN9A, SCN11A, and MPZ) encoding voltage-gated sodium channel and myelin zero protein, 
respectively. Two studies [10,25] reported an association between R1150W mutations in the 
SCN9A gene and chronic NP. Huang et al found eight mutations in the SCN11A gene in 12 
unrelated individuals from a cohort of 345 subjects with painful peripheral neuropathy [32]. 
Ramirez et al reported an association between Trp101stop mutations (MPZ) in individuals affected 
with hereditary neuropathy and debilitating NP [55].  
Genetic association studies 
We identified genetic polymorphisms in or near 34 genes, of which 26 (from CGAS and GWAS) 
were significantly associated with NP in at least one study cohort. Eight genes that had previously 
been postulated as candidates, based on biological evidence, showed no statistical significance in 
their association with NP in our systematic review.: matrix metallopeptidase 1 (MMP1); 
cytochrome P450 Family 2 Subfamily D Member 6 (CYP2D6); transient receptor potential cation 
channel subfamily A member 1 (TRPA1); transient receptor potential cation channel vanilloid 
subfamily member 1 (TRPV1); transient receptor potential cation channel subfamily M member 8 
(TRPM8); brain-derived neurotrophic factor (BDNF); calcium voltage-gated channel alpha2 delta 
2 subunit (CACNAD2); and glutamate ionotropic receptor kainite type subunit 4 (GRIK2). Some 
studies reported genetic variants in human leukocyte genes (HLA-A, HLA-B, HLA-DRB1, and 
HLA-DQB1), catechol-O-Methyltransferase (COMT), opioid receptor Mu 1 (OPRM1), tumour 
necrosis factor alpha (TNFA), interleukin-6 (IL6)  and GTP cyclohydrase (GCH1) that were 
significantly associated with two or more NP conditions. Amongst them, some studies showed 
conflicting results. However, the effect size and direction of those reporting NP associated variants 
were similar across the studies.  We therefore conducted quantitative syntheses, where possible, 
for these variants to assess the level of true associations with NP. Funnel plots and p-values from 
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Egger’s regression test for any possible reporting bias showed no evidence of publication bias (see 
Supplementary Figures S2-S9). However, funnel plots are limited in detecting publication bias 
when there are a small number of studies. All the reported genes from both CGAS and GWAS 
were categorized based on the function or related pathways and only genes significantly associated 
with NP are in bold text, Table 3. Of all the reported genetic variants, 75% are non-coding variants 
that can regulate gene expression and around 40% of these were located in an enhancer region 
(Figure 3).  
Candidate gene association studies 
Neurotransmission 
OPRM1 
The association between A118G (Asn40Asp) in OPRM1 and the risk of developing NP has been 
investigated in three studies [7,29,39]. Cheng et al examined the association of rs1799971 with 15 
painful and 50 painless diabetic foot ulcer patients and reported that patients carrying this variant 
were less susceptible to NP (OR, 0.24; CI, 0.07-0.80, P=3.8×10-02) [7]. In contrast, rs1799971 was 
not significantly associated with NP in individuals with PPSP (P=0.58) [29]. Kalliomaki et al 
showed no significant differences in the distribution of rs1799971 with NP in 47 Swedish subjects 
who had undergone hernia surgery compared with pain-free subjects (P=0.935). This study was 
not considered for meta-analysis because allele frequency data was not reported explicitly [39]. 
The conflicting results might be due to the low number of cases (n<50) and controls (n<115) used 
in these studies. The meta-analysis of two studies [7,29] found that rs1799971 was not significantly 
associated with NP, with no heterogeneity (OR, 0.55; CI, 0.27-1.11; P=0.09) (Figure 4).  
COMT 
COMT encodes catechol-O-methyltransferase and this involved in the breakdown of 
catecholamine neurotransmitters [45]. Five studies in our review interrogated the association of 
rs4680 in COMT with different NP conditions and reported inconsistent results. Armero et al were 
the first to investigate the association between COMT variant and NP, in Spanish patients with 
distinct NP conditions [1]. They found no significant distribution of Val158Met genotypes in NP 
cases compared to healthy controls (P=0.9). Similarly, another Spanish cohort of 109 subjects did 
not show any significant association between COMT and CTS [19]. However, this study reported 
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that CTS subjects carrying the Met/Met genotypes suffered from more pain than others. Another 
study from a Spanish population reported a significant association between rs4680  and NP in 58 
MS patients with pain compared to 50 MS patients without pain (P=4.6×10-02) [20]. These 
conflicting results in the same population may be because they were examining NP of differing 
aetiology. Another cohort of 258 Norwegian subjects with sciatica did not show an association 
between rs4680 and NP risk (P=0.1) [35]. They found a significant association between the Met 
allele of COMT, and pain severity and demonstrated that this may contribute to the progression of 
NP in sciatica patients [35]. Finally, Hegarty et al found no significant association between COMT 
and PPSP [29]. The meta-analysis of all five studies from the European population with a total of 
589 NP cases and 579 controls did not show a significant association between the Met allele of 
COMT and NP (rs4680, OR, 0.95; CI, 0.81-1.13; P=0.584) (Figure 5).  
SCN9A 
SCN9A is involved in ion channel activity. The recent study by Li et al found that four statistically 
significant variants were associated with 887 PDPN cases compared to 1029 controls (rs7449889; 
OR, 2.6; P=4×10-03, rs3750904; OR, 2.2; P=8.96×10-03, rs4369876; OR, 2.1; P=4.7×10-02, 
rs12478318; OR, 2.1; P=4.7×10-02) [42]. Genetic variants in rs4369876 and rs12478318 SNPs in 
SCN9A were also associated with pain severity. 
SLC6A4  
Solute carrier family 6 member 4 protein or serotonin transporter (5-HTT) protein is encoded by 
the SLC6A4 gene on 17q11.2. Cui et al were the first to report an association between 5-HTTLPR 
variant near SLC6A4 and susceptibility to TN. A significant difference in the 5-HTTLPR short-
short genotype distribution was found in the 244 TN patients compared to 280 healthy controls 
from an East Asian ancestry (OR, 5; CI, 1.45-3.17; P=3.4×10-02) [9].  A significant association of 
the 5-HTTLPR short-short genotype with TN pain severity was also reported. This study found no 
association between rs25531 in SCL6A4 and TN risk or pain severity (P<0.05).  
CACNG2 
CACNG2 encodes the transmembrane AMPAR regulatory protein (TARP) gamma-2 which 
modulates neuronal calcium channels [57]. Nissenbaum et al interrogated the association between 
12 polymorphisms in CACNG2 and pain in breast cancer subjects who had undergone breast 
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surgery [51]. A significant association of the A-C-C CACNG2 haplotype (rs4820242-rs2284015-
rs2284017; OR, 1.65; P=1×10-02) with susceptibility to PPSP was reported in this study, though 
they did not confirm that the pain was specifically neuropathic.   
Immune response 
HLA genes 
Six studies included in this review have investigated the association between polymorphisms in 
HLA genes and NP conditions including PHN and PPSP (highlighted in Table 2). Among these, 
three studies examined HLA frequencies in the independent cohorts of subjects with persistent pain 
for more than three months after the disappearance of herpes zoster (HZ) vesicular eruptions, 
subjects with HZ who did not develop PHN, and healthy controls. Ozawa et al were the first to 
report positive associations of the HLA-alleles, HLA-A*33 and HLA-B*44, and an HLA-
DRB1*1302 haplotype with PHN in a Japanese population [53]. Sato et al confirmed these 
associations in the same population [59]. Two studies examined these associations in two 
independent Japanese cohorts that included HZ patients with pain and without pain as well as 
healthy controls [58,63]. These suggested that the risk alleles contribute to the development of 
PHN but are not associated with HZ. A Korean study by Chung et al validated the previously 
reported HLA risk alleles for PHN and found that HLA-B*44 showed the strongest association 
with PHN though not with HZ [8]. In addition, this study reported positive associations of HLA-
B*13, -B*15, DRB1*10.01, and DRB1*1202 with PHN. Dominguez et al reported significant 
associations of HLA-DRB1*04 and HLA-DQB1*03:02 allele frequency and haplotype frequency 
in patients with persistent pain more than six months after surgery, compared to those without 
persistent pain [16]. Although there are differences in HLA allele typing between the studies, we 
combined the frequency of allele subtypes and calculated the OR and CI for meta-analysis. 
The meta-analysis included all studies that found significant associations of HLA-DRB1*13, HLA-
DRB1*04, HLA-A*02, HLA-A*33, HLA-B*44, and HLA-DQB1*03 alleles in two subgroups: 
patients who developed NP after HZ or post-surgery compared with patients who did not develop 
NP after HZ or post-surgery; and patients who developed NP after HZ compared with healthy 
controls. The meta-analysis of four studies [8,53,58,63] found that NP (PHN) is associated with 
HLA-DRB1*13, HLA-DRB1*04, HLA-A*02, and HLA-A*33 compared to healthy controls, with 
no or moderate heterogeneity (OR, 2.96; CI, 1.93-4.56; P=7.9×10-07, OR, 1.40; CI, 1.02-1.93; 
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P=3×10-02, OR, 0.64; CI, 0.47-0.87; P=4×10-03, and OR, 2.41; CI, 1.72-3.39; P=3.9×10-07) (Figure 
6A,C,E,G). The HLA-DRB1*13 allele showed a significant association with NP (PHN, PPSP) 
compared to the subjects with no pain after HZ infection or after inguinal hernia surgery, with no 
heterogeneity (OR, 1.59; CI, 1.04-2.41; P=3.1×10-02) [8,16,58,63] (Figure 6B). The meta-analysis 
of two studies [16,53] found that NP (PHN, PPSP) was associated with HLA-DQB1*03, with no 
heterogeneity (OR, 2.86; CI, 1.57-5.21; P=6×10-04) (Figure 6D). Meta-analysis of HLA-A*02 
alleles from three studies [8,58,63] found a significant protective effect on PHN, with no 
heterogeneity (OR, 0.60; CI, 0.41-0.90; P=1×10-02) (Figure 6F) and HLA-A*33 increased the risk 
of developing NP compared with patients who did not develop NP after HZ (OR, 2.32; CI, 1.42-
3.80; P=8×10-04) (Figure 6H). Meta-analysis found that NP was strongly associated with HLA-
B*44 and that this allele increased the risk of developing NP compared to healthy controls as well 
as HZ patients without PHN (OR, 3.17; CI, 2.22-4.55; P=3.5×10-10 and OR, 3.50; CI, 2-6.11; 
P=1.8×10-05), with very low heterogeneity (Figure 6I,J).   
Cytokines 
Noponen-Hietala et al investigated the association between 16 sequence variations in 10 pro-
inflammatory cytokine genes (interleukins, tumour necrosis factor) and NP. They found a 
significant association between rs13306435 (T15A) in IL6 and NP after correcting for multiple 
testing (rs13306435; OR, 4.4; CI, 1.2-5.7; P=1.1×10-02). The associations between variants in 
IL1A, IL1B and TNFA and NP were not statistically significant after multiple correction [52]. 
Further haplotype analysis using 4 SNPs (rs1800797; G-597A, rs1800796; G-572C, rs1800795; 
G-174C, and rs13306435; T15A) in IL6 showed a significant association with sciatica, and most 
notably, the GGGA haplotype was strongly associated with NP (OR, 5.4; CI, 1.5-9.2; P=3.3×10-
03). Stephens et al reported that 13 SNPs in 7 pro-inflammatory and anti-inflammatory cytokine 
genes (IFNGR1, IL1B, IL2, IL6, IL8, IL17A, NFKB2, and TNFA) were not significantly associated 
with NP after adjusting for covariates such as race, pain before surgery and pain severity after 
surgery [62]. They found that variants in interleukin-1 receptor 2 (IL1R2) (rs11674595; OR, 36.07; 
CI, 2.02-643.37; P=1×10-02) and the CGCGATT haplotype in interleukin-10 (IL10) (rs3024505-
rs3024496-rs1878672-rs1518111-rs1518110-rs3024491) were significantly associated with NP 
after adjusting for covariates (OR, 0.21; CI, 0.05-0.91; P=3×10-02). Kalliomaki et al reported that 
rs1800629 in TNFA was significantly associated with the risk of developing NP in 47 Swedish 
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subjects who had undergone hernia surgery (Relative Risk,1.93; CI, 1.03-3.61; P=3.6×10-02) [39]. 
All of these studies examined different variants in TNFA and were consistent in reporting 
associations with NP.   
Metabolism  
GCH1 
Three studies examined the association of genetic variants in GCH1 with the risk of developing 
NP, in populations with different ancestries. Wadley et al investigated the association of GCH1 
(rs10483639, rs752688, rs4411417, rs8007201, rs3783641, and rs8007267) with NP in HIV-SN 
subjects of black African ethnicity [73]. They found that a 3-SNP haplotype (CAT) and a 6-SNP 
haplotype (CTCGAT) were associated with a lower risk of having NP (P=2×10-02, and P=4×10-02) 
but no single SNP showed an association with NP. Kalliomaki et al found no significant 
association of the rs8007267-rs3783641-rs10483639 haplotype in GCH1 with NP in 47 Swedish 
subjects who had undergone hernia surgery [39]. Hegarty et al reported a significant association 
between the C allele of rs8007267 in GCH1 and PPSP (P=2×10-02) but not with other SNPs 
(rs3783641, rs10483639) [29]. A meta-analysis could not be performed because not all studies 
provided genotype information.  
Iron metabolism-related genes 
Kallianpur et al studied the association between genetic variants in 19 iron-regulatory and iron-
transport-pathway genes and distal peripheral neuropathic pain (DPN) in 168 HIV-SN subjects 
from an ad-mixed American population [38]. They found significant associations between DPN 
and seventeen variants in eight genes encoding: Aconitase 1 (ACO1), Beta-2-Microglobulin 
(B2M), Bone morphogenetic protein 6 (BMP6), Frataxin (FXN), Ceruloplasmin (CP), Transferrin 
(TF), Transferrin cell surface receptor (TFRC), and Solute carrier family11 member2 (SLC11A2). 
Polymorphisms (rs2026739, and rs7033149) at 9p21.1 in ACO1 were associated with increased 
risk (OR, 1.5; CI, 1.1-2.0; P=7×10-03 and OR, 1.6; CI, 1.1-2.4; P=1.2×10-02) and rs4495514 in 
ACO1 was associated with a decreased risk of developing NP in HIV-SN subjects (OR, 0.4; CI, 
0.2-0.9; P=3.6×10-02). They reported that rs16966334 and rs1901531 in B2M (OR, 2.4; CI, 1.3-
4.2; P=3×10-03, and OR, 1.6; CI, 1.1-2.5; P=2.8×10-02) and variants in CP increased the risk of 
developing NP (rs13072552; OR, 1.6; CI, 1.1-2.4; P=7×10-03, rs13075921; OR, 1.6; CI, 1.0-2.4; 
P=4.8×10-02, and rs3816893; OR, 1.9; CI, 1.2-3.0; P=4×10-03). They also found that rs270388, 
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rs267202, and rs267206 in BMP6, were significantly associated with NP (OR, 1.3; CI, 1.0-1.8; 
P=5×10-02, OR, 0.8; CI, 0.6-1.0; P=5×10-02, and OR, 1.4; CI, 1.0-2.0; P=3×10-02). An iron-related 
SNP, rs3793451 at 9q21 in FXN was significantly associated with lower risk of developing DPN 
(OR, 0.4; CI, 0.2-0.9; P=4.7×10-02).  Significant associations between two SNPs in TF and distal 
NP was found in HIV-SN subjects of mixed ancestry (rs2718796; OR, 3.1; CI, 1.4-7.3; P=7×10-03 
and rs8177306; OR, 0.4; CI, 0.2-0.9; P=2.3×10-02).  This study also reported significant 
associations between the T allele of rs480760 in TRFC and rs224446 in SLC11A2, and NP (OR, 
0.6; CI, 0.4-0.9; P=4×10-03, and OR, 0.7; CI, 0.4-1.0; P=4.7×10-02). They also reported associations 
between these SNPs and greater severity of DPN both in black and white non-Hispanic populations 
(P < 5×10-02). 
Genome-wide association studies 
Receptor signalling 
GFRA2 
The first published GWAS study on neuropathic pain performed by Meng et al reported suggestive 
significant SNPs (P<10-6) at 8p21.3 near GFRA2 (glial cell-line derived neurotrophic factor 
receptor alpha 2), which is related to the receptor signalling pathway as well as to the immune 
response. In this study, a total of 572 diabetes patients with NP cases, defined by their prescription 
history and a positive monofilament sensory test on the foot, were compared with 2491 diabetic 
patients without NP in the Scottish population-based GoDARTS cohort [47]. The most significant 
intergenic SNP, rs17428041 near GFRA2, showed borderline significance in association with NP 
(OR, 0.67; CI, 0.57-0.78; P, 1.77×10-7).  
PRKCA 
PRKCA (protein kinase C alpha) encodes for protein kinase C alpha protein and is involved in 
neurotransmission and apoptosis signalling. Warner et al found an association between a variant, 
rs887797, in PRKCA that reached suggestive significance (P=4.29×10-06) and possible NP subjects 
who had undergone post total joint replacement. This finding was validated in two independent 
UK cohorts of individuals who had undergone hip or knee replacement and individuals with knee 
pain and screened for NP using the painDETECT questionnaire from the Rotterdam study [75]. 
They conducted a meta-analysis of these cohorts which showed a suggestive association of 
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rs887797 in PRKCA with NP (OR, 2.41; CI, 1.74-3.34; P=1.29×10-07) in the random effects 
recessive model.  
Immune response / Ion binding 
HMGB1P46 / ZSCAN20-TLR12P 
A gender specific GWAS reported a suggestively significant intergenic SNP at 8q23.1 mapped to 
nearby HMGB1P46 and NP in male individuals with diabetes compared with patients without NP 
in the Scottish population-based GoDARTS cohort (rs6986153; OR, 1.67; CI, 1.34-2.08; 
P=8.02×10-7) [46]. Meng et al also reported a suggestively significant intergenic SNP at 1q35.1 
mapped to nearby ZSCAN20-TLR12P (zinc finger protein-toll-like receptor) and NP in female 
individuals with diabetes (rs71647933; OR, 2.31; CI, 1.68-3.17; P=2.74×10-7) [46].  
Discussion 
This systematic review has summarized 29 genetic studies in humans that have interrogated the 
relationship between genetic factors and the presence of different neuropathic pain conditions. All 
included studies in this review have defined the NP cases based on clinical examination or clinical 
assessment or pain questionnaire or prescription history, and controls as either healthy controls or 
patients without pain at the time of the study. We identified several genetic associated variants in 
twenty-eight genes that are involved in various biological pathways including neurotransmission, 
receptor signalling, immune response, iron metabolism, drug metabolism, receptor binding and 
ion binding. The majority of reported variants near genes overlap with enhancer or promoter 
histone markers, and few genes are transcription factors and targets for microRNAs. This indicates 
that few of these variants influence protein expression directly, and that most only indirectly 
influence the expression of genes. It suggests that epigenetic mechanisms may contribute to NP 
risk. However, the majority of the included studies had small sample sizes and lacked validation. 
One potential limitation of all included studies in this review was the employment of varying case 
definitions, and uncertain control ascertainment, irrespective of different NP conditions. Very few 
studies addressed the exclusion of controls based on co-morbidities related to any pain. Moreover, 
few candidate gene association studies tested the association of variants using a model without 
multiple adjustments. Most importantly, only a small number of studies have adjusted the 
association model with either more general covariates such as age, gender, smoking, and BMI or 
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with study-specific covariates such as pain severity, ethnicity, surgery type and therapy. Some 
studies had not reported summary statistics in detail. The GWAS in this field are few and have 
failed to replicate previously reported genes, perhaps due to small sample size or differences in 
case definition. In future studies, these limitations need to be considered and resolved. 
Traditional molecular genetics studies found gain-of-function mutations in SCN9A, SCN11A, and 
Trp101stop mutations in NP patients compared to the healthy controls. SCN9A and SCN11A are 
mainly expressed in nociceptive sensory neurons of the dorsal roots and play an important role in 
regulating pain signals [2,56]. Evidence suggests that the sodium channel genes, Nav 1.9 and Nav 
1.7 could be used as molecular targets for treating NP [18]. The most significant association 
between non-synonymous variant (rs3750904) in SCN9A and NP in diabetes patients has been 
confirmed in a genetic association study [42]. Moreover, these studies have identified potential 
candidate genes for future association studies. MPZ was only identified in a single study with a 
specific NP condition, and conclusions must be limited. To date, three GWA studies on different 
NP conditions (PDPN and PPSP) have identified suggestive signals (P<5×10-06) at chr8p21.3, 
chr1p35.1, chr8p23.1, and chr17q24.2 loci, in discovery cohorts from the European population, 
and the association of chr17q24.2 (PRKCA) with NP was confirmed in an independent cohort of 
subjects with knee or hip replacement surgery. Other loci, chr8p21.3, chr1p35.1, and chr8p23.1, 
associated with NP in a diabetes population, have not been confirmed in replication cohorts, and 
this may be because of differences in case definition or lack of appropriate sample sizes. Of the 
CGAS reviewed in this study, variants within SCN9A, IL10, IL1R2, B2M, BMP6, TF, CP, TFRC, 
ACO1, FXN, SLC6A4, and CACNG2 were only interrogated in single studies and significantly 
associated with NP but this needs to be validated in larger sample sizes. Genetic variants in COMT, 
HLA genes, OPRM1, GCH1, IL6 and TNFA were investigated their association with NP in more 
than one study.  
The most extensively studied candidate variant is A118G in exon 1 of OPRM1 in several pain 
conditions; this has been found to be associated with lower pain levels and is mainly involved in 
neurotransmission pathways. This missense variant at 6q25.2 results in an amino-acid substitution 
(Asn40Asp) which may increase the binding affinity of β-endorphin. Meta-analysis of two studies 
found no significant association between rs1799971 in OPRM1 and NP. However, replication 
cohorts with larger sample sizes are necessary to validate these findings. A systematic review and 
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meta-analysis study has reported that individuals carrying the Met allele of COMT are more 
susceptible to other types of chronic pain and to severity of pain [64]. Our meta-analysis results 
found that COMT was not significantly associated with NP; although one study reported a 
significant association with NP in MS patients, other studies reported non-significant associations 
with sciatica, PHN, and PPSP. Further studies with larger sample size and consistent case and 
control definitions may reveal the true association of COMT variants with NP.  
Evidence suggests that polymorphisms in GCH1 decrease pain levels by altering the expression of 
this enzyme [44,66]. One study found a positive association between an intronic variant, 
rs8007267, in GCH1 and PPSP. Two studies investigated the association of GCH1 haplotypes 
(rs752688, rs3783641, rs8007201) with NP and reported inconsistent results. Larger cohort studies 
might validate the association of rs8007267 with NP, confirm the haplotypes association, and 
identify more NP susceptibility variants in GCH1.  
The HLA gene complex is a highly polymorphic region located on the short arm of chromosome 
6 and comprises more than 200 genes. Association between HLA genes and NP in herpes zoster 
patients (PHN) are the most studied in the East Asian population and one study investigated this 
relationship in a European population. Our fixed effect meta-analyses result found that 
polymorphisms in HLA-DRB1*13, HLA-DRB1*04, HLA-DQB1*03, HLA-A*33, and HLA-B*44 
showed significant increases in the risk of having NP and effect sizes and direction were consistent 
across the studies. In contrast, HLA-A*02, a protective allele, conferred reduced risk for NP. Only 
moderate heterogeneity was observed in HLA-DRB1*04 and HLA-A*02 combined analyses due to 
different ethnicity. Apart from HLA genes, cytokines such as IL6 and TNFA have been shown to 
be linked to several chronic pain conditions [40] and variants in TNF haplotypes have been shown 
to be associated with pain severity in HIV-SN patients of South African ancestry [30]. 
Interestingly, activation of immune cells and then overexpression of pro-inflammatory cytokines 
has been seen in neuropathic pain patients [3,69].Our review also found two studies that examined 
the contribution of several variants in inflammatory cytokine genes to the risk of developing NP 
and found that IL6, IL10, IL1R2, and TNFA were significantly associated with NP but these studies 
explored different variants in these genes and were limited by study sample size. Therefore, we 
could not combine these studies to assess their true association with NP susceptibility. However, 
large-scale studies would reveal the relationship between inflammatory response and its role in the 
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pathophysiology of NP. These studies demonstrate that further investigation of polymorphisms in 
HLA genes and inflammatory genes could identify potential genetic variants which could be used 
as drug targets for NP to modulate the immune responses. 
Limitations of the included studies 
Strengths and limitations of this review 
To our knowledge, this systematic review is the first to date summarizing the genetic factors that 
contribute to the risk of developing NP in humans. Recent reviews focussed on the risk factors, 
including genetic factors, for specific conditions including PDPN and PHN [21,26]. Strengths of 
this review include the literature search for articles reporting molecular genetic findings and 
genetic association studies in five databases, applying a standard study design according to 
PRISMA guidelines, employing explicit search terms using previously validated keywords, 
utilizing text mining methods to filter studies based on appropriate inclusion and exclusion criteria, 
updating recent records using original search strategies, and employing data synthesis of all 
eligible genetic association studies. We employed standard meta-analysis study design and 
reporting methods according to STREGA quality guidelines for genetic association studies.  
This review excluded non-English language articles and may therefore have missed any important 
new findings reported in other languages. Our meta-analyses results were limited by the small 
sample sizes of relatively few eligible studies and this may affect the robustness of the results.  For 
example, heterogeneity is difficult to estimate when studies are few in number [23,31]. A few 
included studies in this review explored the association of SNPs with NP as well as pain severity; 
this review focussed only on genetic factors for the risk of developing NP and may not have 
captured neuropathic pain severity associated genetic variants. These variants may be involved in 
NP susceptibility as well, and we may have missed them. Our included studies examined genetic 
factors associated with NP in studies that reported both human and experimental animal models as 
well but we have not considered results from animal model studies alone. The translation of animal 
model studies to human is still under debate, especially in this field. Finally, a few included studies 
from the same research group may overlap with each other.   
Recommendations for future research 
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Our systematic review highlights the current knowledge of genetic factors that influence the risk 
of having NP and reveals recommendations for future studies. Our review lists potential candidate 
genes which can be validated in further studies with large sample sizes from different ethnic 
groups. In addition, future haplotype analysis could reveal the true association of haplotype blocks 
in candidate genes with NP susceptibility. A large-scale GWAS with consensus NP phenotype in 
independent cohorts could shed light on other potential genetic polymorphisms across the genome 
associated with NP susceptibility or protection. Pathway analysis could explore additional genes 
involved in the immune response, neurotransmission and metabolism pathways which would be 
useful to identify multiple genes in pathways that contribute to NP susceptibility. In addition, 
exome sequencing might identify common and rare causal variants associated with NP risk. 
Conclusions 
This systematic review gathered all genetic studies in humans and identified several variants in or 
near twenty-eight genes significantly associated with NP. Our meta-analysis results suggest that 
variants in HLA-DRB1*13, HLA-DRB1*04, HLA-DQB1*03, HLA-A*33, and HLA-B*44 increase 
the risk of developing NP, whereas variants in HLA-A*02 decrease the risk and variants in COMT, 
and OPRM1 were not associated with NP. However, larger cohort studies are necessary to validate 
these findings, and these could identify biomarkers for clinical prognosis and drug targeting. The 
limited number of case-control GWAS on NP highlights the need for large-scale GWAS with a 
consistent case definition. Our review suggests that multiple genetic risk factors from distinct 
pathways influence NP susceptibility, and their interactions may elucidate the genetic mechanisms 
underlying NP.  
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Figure Legends 
Figure 1. PRISMA flow diagram represents the systematic literature search and assessment 
process. 
Figure 2. The number of published genetic studies on different neuropathic pain conditions 
included in this review.  
Figure 3. Genomic features of all reported SNPs (in %) that are associated with neuropathic pain. 
Figure 4. Forest plots of studies reporting the associations between rs1799971 in OPRM1 and 
neuropathic pain either in diabetic patients or patients who had undergone surgery. Effect allele is 
G.  
Figure 5. Forest plots of studies reporting the associations between rs4680 in COMT and distinct 
neuropathic pain conditions including surgery, sympathetic reflex dystrophy, causalgia, phantom 
limb, multiple sclerosis, postherpetic neuralgia, peripheral neuralgia, carpal tunnel syndrome, and 
central neuralgia. Effect allele is A.  
Figure 6. Forest plots of studies reporting the associations between polymorphisms in HLA genes 
and neuropathic pain (NP) either in herpes zoster patients or patients who had undergone surgery. 
Sub grouped by the association results from patients with NP vs. without pain and patients with 
NP vs. healthy controls.  A) HLA-DRB1*13 allele frequencies in patients with NP vs. healthy 
controls. B) HLA-DRB1*13 allele frequencies in patients with NP vs. without pain. C) HLA-
DRB1*04 allele frequencies in patients with NP vs. healthy controls. D) HLA-DQB1*03 allele 
frequencies in patients with NP vs. without pain/healthy controls. E) HLA-A*02 allele frequencies 
in patients with NP vs. healthy controls. F) HLA-A*02 allele frequencies in patients with NP vs. 
without pain. G) HLA-A*33 allele frequencies in patients with NP vs. healthy controls. H) HLA-
A*33 allele frequencies in patients with NP vs. without pain. I) HLA-B*44 allele frequencies in 
patients with NP vs. healthy controls. J) HLA-B*44 allele frequencies in patients with NP vs. 
without pain. 
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A systematic review and meta-analysis of genetic risk factors for neuropathic pain 
Table 1. Characteristics of included studies in the systematic review. 
Year Study Study 
type 
Ethnicity Sample size 
(cases/controls) 
Mean Age 
(cases/controls) 
Sex 
(M:F) 
NP case definition NP condition Control definition 
2005 Armero et al. (1) CGAS Spanish 283 
(144/139) 
NR NR Diagnosis of NP  NP 
of different 
aetiology 
Healthy subjects 
without a history 
of pain 
2011 Binder et al.(2) CGAS German 624 
(371/253) 
56.4/27.6 157:214/80:173 Expert physician 
examination; 
QST 
NP of 
different 
aetiology 
Healthy 
volunteers 
2010 Cheng et al.(3) CGAS Taiwan 65 
(15/50) 
67.5/65 11:4/26:24 Diabetics patients 
had foot ulceration 
at least 4 weeks 
and Grades 3-5 
pain occurrence; 
diagnosed by foot 
tests and VAS for 
pain intensity ≥ 4 
DFU patients 
with pain 
Painless DFU 
patients  
(VAS for pain 
intensity ≤ 3)  
2016 Chung et al.  (4) CGAS Korean 355 
(66/54,235) 
64.7/53.7 34:32/20:34 Persistent pain > 3 
months after HZ 
onset, received 
treatment. 
PHN Herpes Zoster 
without pain, 
Healthy subjects 
2014 Cui et al. (5) CGAS Han Chinese 524 
(244/280) 
55/54.9 100:144/112:168 Screening: 
Idiopathic TN. 
Facial pain: IASP 
criteria. Clinical, 
Neurological 
examination 
TN Healthy 
volunteers 
2011 Dabby et al.(6)  Genetic 
studies 
Jewish, 
Israel 
59 
(9/50) 
NR NR Clinical, 
neurological, MRI 
examination, QST, 
VAS pain intensity 
scale 
Chronic 
severe NP 
Healthy controls 
Table
2 
 
2013 Dominguez et al. 
(7) 
CGAS Swedish 
 
189 
(94/95) 
 
21-86 years 179:10 Inguinal Pain 
Questionnaire 
collection after 6 
months of surgery, 
clinical examination 
by physician; pain 
PPSP after 
inguinal 
surgery 
Pain-free after 
inguinal surgery 
2013 Fernandez-de-las-
Penas et al. (8)  
CGAS Spanish 108 
(58/50) 
44/45 29:29/20:30 Screening: MS with 
EDSS score and 
clinical 
questionnaire - 
neurogenic pain 
location intensity 
NP due to MS MS patients 
without pain 
2013 Fernandez-de-las-
Penas C et al. (9) 
CGAS Spanish 218 
(109/109) 
47/46 0:109/0:109 Screening: CTS by 
clinical and 
electrophysiological 
examination, pain 
score using BCTQ 
NP due to CTS Healthy women 
without any 
upper extremity 
symptom 
2014 Harrer et al. (10) Genetic 
mutation 
analysis 
Caucasian  2 
(2/-) 
46/- 0:2/- Clinical evaluation 
and 
electrophysiological 
testing 
Nerve pain - 
2012 Hegarty et al. (11) CGAS European 52 
(20/32) 
40/39 9:11/19:14 Presence of pain 
reported 3 months 
after surgery. 
Higher pain score 
compared to pre-
operative pain 
score (VAS score), 
Neurological 
examination - MRI 
& positive straight 
leg testing, 
Neurophysiological 
assessment - QST 
PPSP after 
lumbar 
discectomy 
Individuals 
without pain after 
lumbar 
discectomy 
2014 Huang et al. (12) Genetic 
mutation 
analysis 
Netherlands 
and UK 
1039 
(345/694) 
49/- NR Screening: possible 
painful peripheral 
neuropathy 
Painful 
peripheral 
neuropathy 
Healthy controls 
3 
 
2013 Jacobsen M et al. 
(13) 
CGAS Norway 
(European 
white) 
510 
(257/253) 
41/41 137:120/131:122 Lumbar disc 
herniation ; Follow-
up examination 
sensory, motor, 
lower limb and MRI 
Low back 
pain, Sciatica 
pain 
Pain-free controls 
without a history 
of back disease 
2012 Jacobsen et al. 
(14) 
CGAS European 
Caucasian 
507 
(258/249) 
41/41 138:120/129:120 Neurological 
examination – MRI 
& positive straight 
leg testing 
Sciatica pain 
after disc 
herniation 
surgery 
Healthy subjects 
without of history 
of pain and back 
disease 
2014 Kallianpur et al. 
(15) 
CGAS Non-
Hispanic 
blacks  
or  
non-
Hispanic 
whites 
558 
(168/390) 
46/43 125:43/316:74 Screening: DPN due 
to HIV-SN, clinical 
examination by 
experts and self-
reported 
questionnaire 
reported bilateral 
presence of pain 
symptoms 
DNP due to 
HIV-SN 
Controls without 
any sensory pain 
signs or 
symptoms of 
peripheral nerve 
disease 
2016 Kalliomaki et al. 
(16) 
CGAS Swedish 140 
(47/93) 
55.4/58 41:6/87:6 Inguinal pain 
questionnaire, 
clinical examination 
– sensory test 
PPSP 
(probable NP) 
Patients without 
pain after the 
surgery 
2015 Li et al.(17) CGAS European 
ancestry 
(US and 
Canada) 
1916 
(887/1029) 
59.8/>54 NR Screening: DPN 
symptoms using 
neurological 
examination 
PDPN –  pain 
scored by clinical 
assessment 
PDPN Subjects not 
having NP 
2014 Meng et al. (18) GWAS Scottish 3063 
(572/2491) 
66.82/66.86 297:275/1503:988 Screening: Diabetic 
neuropathy. 
Monofilament test, 
first-line NP drugs 
PDPN Diabetic patients 
without an record 
of first-line drugs 
or any opioid 
drugs for NP 
2015 Meng et al. (19) GWAS Scottish 4221 
(961/3260) 
72.6/75.5 470:491/2021:1239 Multiple 
prescriptions : First-
line drugs for 
painful diabetic 
PDPN Diabetic patients 
without an record 
of first-line drugs 
4 
 
peripheral 
neuropathy (PDPN) 
2010 Nissenbaum et al. 
(20) 
CGAS Israeli 
Jewish 
549 
(215/334) 
52.9 0:549 Pain after unilateral 
mastectomy; pain 
reported by 
patients during 
interview 
PPSP after 
mastectomy 
Women 
undergone 
mastectomy 
without pain 
2005 Noponen-Hietala 
et al. (21) 
CGAS Finnish 334 
(155/179) 
44/39 94:61/56:123 Unilateral shooting 
sciatic pain - 
Clinical 
presentation and 
MRI examination, 
VAS and Oswestry 
disability scale 
Sciatica pain Healthy subjects 
1999 Ozawa et al. (22) CGAS Japanese 168 
(32/136) 
 
163 
(27/136) 
74.8/- 14:18/- 
 
 
 
Screening: PHN 
(duration of disease 
3 to 244 months) 
 
PHN Healthy subjects 
2012 Ramirez et al. (23) Genetic 
mutation 
analysis 
Caucasian 
population 
2 
(2/-) 
Age onset 1st 
to 4th decade 
female QST examination , 
Validated scale 
assessment for 
assessing 
impairment in CMT 
– CMTNS, QST, Skin 
biopsy 
Definite NP 
due to CMT 
Healthy controls 
2002 Sato et al. (24) CGAS Japanese 165 
(40/125) 
68.3/40 17:23/75:50 PHN defined as 
revisit >90 days 
after onset, 
received treatment. 
VAS score >50 
 
PHN Healthy subjects 
without 
medication and a 
history of herpes 
zoster 
2004 Sato-Takeda et al. 
(25) 
CGAS Japanese 239 
(52/(42,125)) 
70.1/58.3,44.
5 
21:31/17:25,75:50 Persistent pain > 3 
months after HZ 
onset, received 
treatment. VAS 
score >30 
PHN Herpes Zoster 
without pain, 
Healthy subjects 
5 
 
2014 Stephens et al. 
(26) 
CGAS Multiple 
ethnicity 
(USA) 
172 
(46/126) 
52.4/58.6 0:46/0:126 Screening: Adult 
woman who had 
undergone breast 
cancer surgery and 
pain ratings using 
questionnaire 
NP after 
breast 
removal 
surgery; pain 
score above 6 
No pain after 
breast removal 
surgery; 
Pain score 0 
2008 Sumiyama et al. 
(27) 
CGAS Japanese 348 
(70/(80,52,1
40)) 
NR NR Persistent pain > 3 
months after HZ 
onset 
PHN PHN-, 
Herpes Zoster-, 
Healthy subjects 
2012 Wadley et al. (28) CGAS South 
Africans 
159 
(144/15) 
41/41 35:124 Screening: HIV-SN 
Bilateral presence 
of at least 1 NP 
pain symptom and 
clinical sign 
(vibration sense 
test); pain intensity 
score 
HIV-SN 
patients with 
pain 
HIV-SN patients 
without pain 
2017 Warner et al. (29) GWAS Discovery 
United 
Kingdom 
 
Replication 
United 
Kingdom   
 
Netherlands 
Discovery 
613 
(109/504) 
 
Replication 
212 
(30/182) 
 
908 
(192/716) 
NR NR Screening: NP in 
individuals with 
post-total hip or 
knee replacement 
identified by pain 
DETECT 
questionnaire. 
Score > 19 and anti-
neuropathic 
medication 
PPSP after 
hip/knee 
replacement 
surgery 
Patients without 
pain after the 
surgery 
CTS, carpal tunnel syndrome; CMT, Charcot Marie tooth syndrome; DFU, diabetic foot ulcer; DPN, distal painful peripheral neuropathy; HIV-SN, human immunodeficiency virus 
– sensory neuropathy; MS, multiple sclerosis; NP, neuropathic pain; PHN, postherpetic neuralgia; HZ, Herpes Zoster; PDPN, painful diabetic peripheral neuropathy; PPSP, 
persistent post-surgical pain; TN, trigeminal neuralgia. CGAS, candidate genetic association study; GWAS, genome-wide association study; QST, quantitative sensory testing; 
IASP, international association for the study of pain; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; NR, not reported; sample size – number of 
samples included for genetic association studies.  
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Table 2. Summary of reported statistical methods, and outcomes from all included studies and estimated quality score for each 
study. 
Year Study Genotype 
method 
Genetic 
markers 
HWE Effect 
allele 
Analysis Adjusted to 
covariates 
OR (95% CI) 
/ 
P-value 
Outcome STREGA 
score 
(Maximum 
score =30 ) 
2005 Armero et al. (1) PCR Chr22q11 
Val158Met 
NR A Chi-Square 
test 
- COMT 
Not given; Calculated 
1.03(0.74–1.44)/0.9 
Not 
associated 
with NP 
19 
2011 Binder et al.(2) Pyrosequencing TRPA1 
rs13268757 
rs920829 
rs959976 
TRPV1 
rs8065080 
rs222747 
TRPM8 
rs13004520 
rs2890163 
rs11562975 
rs17868387 
rs7593557 
rs17862932 
Y  
C 
G 
A 
 
A 
C 
 
G 
A 
G 
A 
G 
C 
Chi-Square 
test and Yates 
corrected 
- TRP genes 
P = not significant 
Not 
associated 
with NP 
21 
2010 Cheng et al. (3) PCR OPRM1 
A118G  
rs1799971 
 
Y G Fisher’s exact 
test/ Chi-
Square test 
- OPRM1 
0.24(0.07-0.8)/0.038 
 
Associated 
with DFU pain 
23 
2016 Chung et al. (4) PCR SNPs in HLA-
A, -B, -C, 
 HLA-DRB1 
NR - Fisher’s exact 
test/ Chi-
Square test 
- HLA-B*44 
PHN vs HZ 
3.84(1.25-
11.79)/0.012 
PHN vs controls 
1.83(0.99-
3.40)/0.049 
HLA-B*15 
PHN vs controls 
Associated 
with PHN 
25 
7 
 
3.68(1.17-
11.61)/0.029 
HLA-C*01 
PHN vs controls 
0.54(0.29-
0.98)/0.004 
HLA-C*12 
PHN vs controls 
0.11/0.048 
HLA-DRB1*01 
PHN vs controls 
0.19(0.05-0.81)/0.01 
HLA-DRB1*10 
PHN vs controls 
4.86(1.07-22)/0.04 
2014 Cui et al. (5) PCR 5-HTTLPR 
 
 
 
 
 
rs25531 
Y 
 
 
 
 
 
Y 
Short 
 
 
 
 
 
A 
Multi-variate 
logistic 
regression 
Age, sex, 
smoking 
status 
SLC6A4 
5-HTTLPR 
1.891(1.478-
2.418)/0.045 
 
 
rs25531 
0.99(0.774-
1.258)/0.913 
5-HTTLPR 
associated 
with TN 
susceptibility 
and pain 
severity 
Not 
associated 
with TN  
26 
2011 Dabby et al. (6) PCR, 
fluorescently 
labelled 
dideoxynucleosi
de terminators 
W1550R 
mutation 
- - Mutation 
analysis 
- SCN9A Gain-of-
function 
mutation 
NA 
2013 Dominguez et 
al. (7) 
PCR,Human660-
Quad Illumina 
chip 
HLA*IMP 
DRB1*04, 
DQB1*03:02 
 
NR - Chi-Square 
test, 
Bonferroni 
corrections 
- DRB1*04 
2.28(1.32-3.96) / 
0.05 
DQB1*03:02 
3.16(1.61-6.22) / 
0.01 
HLA variants 
associated 
with risk of 
developing NP 
24 
2013 Fernandez-de-
las-Penas et al. 
(8) 
TaqMan drug 
metabolism 
rs4680 
Val158Met 
Y A Chi-Square 
test 
- MS with pain vs. 
without pain 
COMT 
Associated 
with NP in MS 
23 
8 
 
genotype assay, 
real time PCR 
P=0.046 
2013 Fernandez-de-
las-Penas et al. 
(9) 
TaqMan rs4680 
Val158Met 
Y A Chi-Square 
test 
- Carpal Tunnel 
Syndrome 
COMT 
P=0.780 
Calculated  
0.9(0.62-1.32) 
 
Not 
associated 
with pain 
susceptibility 
(CTS) 
Associated 
with pain 
severity 
23 
2014 Harrer et al. 
(10) 
PCR/Sequencing R1150W 
variant 
- - Sequence 
comparison 
with reference 
genome 
- SCN9A 
- 
Missense 
mutations of 
Nav1.9 
 
NA 
2012 Hegarty et al. 
(11) 
TaqMan rs3783641 
rs8007267, 
rs10483639, 
rs1799971, 
rs4680, 
rs3892097 
NR T 
C 
G 
A 
A 
C 
Pearson’s’ Chi-
Square test 
- GCH1 – CC 
P=0.02, 
OPRM1, 
COMT, CYP2D6 
P=not significant 
A SNP in GCH1 
associated 
with NP 
Not 
associated 
with NP 
21 
2014 Huang et al. 
(12) 
PCR SCN11A 
variants 
- - Sequence 
comparison 
with healthy 
controls 
- SCN11A 
- 
R1150W 
substitution of 
the Nav1.7. 
Gain-of-
function 
mutation 
NA 
2013 Jacobsen et al. 
(13) 
TaqMan rs1799750 Y G Chi-Square 
test 
- MMP1 
P=0.819 
Not 
associated 
with NP 
susceptibility 
but with pain 
severity 
23 
2012 Jacobsen  et al. 
(14) 
TaqMan  rs4680 
Val158Met 
Y A Chi-Square 
test 
- COMT 
P=0.143 
 
Not 
associated 
with NP 
Associated 
with pain 
progression 
23 
9 
 
2014 Kallianpur et al. 
(15) 
Affymetrix 6.0 rs2718796 
rs8177306 
rs13072552 
rs13075921 
rs3816893 
rs480760 
rs270388 
rs267202 
rs267206 
rs7033149 
rs4495514 
rs2026739 
rs3793451 
rs224446 
rs16966334 
rs1901531 
NR G 
G 
T 
C 
T 
T 
T 
A 
C 
G 
T 
G 
T 
T 
G 
C 
Multi-variate 
logistic 
regression, 
Pearson’s Chi-
Square test 
Multiple 
testing 
Age, total D-
drug 
exposure, 
CD4+ T-cell 
nadir, 
plasma HIV 
RNA 
concentratio
n, all 4 PCAs 
TF 
3.1 (1.4–7.3)/ 0.007 
0.4 (0.2–0.9)/ 0.023 
CP 
1.6 (1.1–2.4)/ 0.007 
1.6 (1.0–2.4)/ 0.048 
1.9 (1.2–3.0)/ 0.004 
TFRC 
0.6 (0.4–0.9)/ 0.042 
BMP6 
1.3 (1.0–1.8)/ 0.057 
0.8 (0.6–1.0)/ 0.050 
1.4 (1.0–2.0)/ 0.029 
ACO1 
1.6 (1.1–2.4)/ 0.013 
0.4 (0.2–0.9)/ 0.040 
1.5 (1.1–2.0)/ 0.009 
FXN 
0.4 (0.2–0.9)/ 0.046 
SLC11A2 
0.7 (0.4–1.0)/ 0.047 
B2M 
2.4 (1.3–4.2)/ 0.003 
1.6 (1.1–2.5)/ 0.028 
8 iron-related 
genes 
significantly 
associated 
with DPN. 
Associated 
with DPN 
severity 
25 
2016 Kalliomaki et al. 
(16) 
TaqMan rs1800629 
 
 
rs5030977 
 
 
 
 
rs6691840 
 
 
rs6265 
 
 
NR G 
 
 
G 
 
 
 
 
T 
 
 
G 
 
 
Chi-Square 
test 
- TNF-α 
RR(95% CI) 
1.93(1.03-
3.61)/0.036 
CACNAD2 
rs5030977 
 1.14 (0.66–
2.00)/0.603 
GRIK3 
1.16 (0.70– 
1.92)/0.247 
BDNF 
0.96 (0.58–
1.61)/0.340 
TNF-α, 
associated 
with NP 
 
Not 
associated 
with NP 
 
Not 
associated 
with NP 
Not 
associated 
with NP 
25 
10 
 
 
rs1799971 
 
rs8007267 
rs3783641 
rs10483639 
 
A 
 
A 
T 
G 
OPRM1 
0.98 (0.57–
1.68)/0.935 
GCH1 haplotype 
Not significant 
Not 
associated 
with NP 
Not 
associated 
with NP 
2015 Li et al. (17) PCR – ligand 
detection 
reaction 
rs74449889 
rs3750904 
rs4369876 
rs12478318 
Y G 
C 
A 
G 
Fisher’s exact 
test/ Chi-
Square test 
- SCN9A 
2.6/0.028 
2.2/8.96e-03 
2.1/0.047 
2.1/0.047 
Associated 
with PDPN 
susceptibility 
and pain 
severity 
25 
2014 Meng et al. (18) Affymetrix 6.0 
Illumina 
1000G 
Imputation 
rs17428041 
 
Y C Fisher’s exact 
test with 
multiple 
testing 
 
Gender, BMI GFRA2 
0.67(0.57-
0.78)/1.77x10-7 
Borderline 
significance 
with PDPN 
25 
2015 Meng et al. (19) Affymetrix 6.0 
Illumina 
1000G 
Imputation 
rs71647933 
 
 
rs6986153 
 
Y 
 
 
Y 
G 
 
 
G 
Fisher’s exact 
test with 
multiple 
testing; 
Gender-
specific test 
Gender, BMI ZSCAN20-TLR12P 
1.65(1.36-
2.02)/4.88x10-7 
(All) 
2.31(1.68-
3.17)/2.7488x10-7 
(Female) 
HMGB1P46 
1.67(1.34-
2.08)/8.02x10-7 
(Male) 
Borderline 
significance 
with PDPN 
26 
2010 Nissenbaum et 
al. (20) 
PCR rs4820242 
rs2284015 
rs2284017 
rs2284018 
rs1883988 
 
NR A 
C 
C 
T 
A 
Logistic 
regression 
Permutation 
analysis 
Haplotype 
analysis 
Ethnicity, 
Chemothera
py, 
Surgery 
type, 
Years since 
operation 
 
CACNG2 
P=0.02, 
P=0.02, 
P=0.04, 
P=0.05, 
P=0.03, 
Haplotype blocks 
(rs4820242,rs228401
5, rs2284017) 
1.65(NA)/0.001 
Associated 
with NP 
20 
11 
 
2005 Noponen-
Hietala et al. 
(21) 
PCR IL-6 
rs13306435 
(T15A) 
rs1800797 
(G-597A) 
rs1800795 
(G-174C) 
rs1800796 
(G-572C) 
TNFA 
rs1800629 
(G-308-A) 
NR T 
 
 
G 
 
G 
 
G 
 
 
G 
Chi-Square 
test, 
Haplotype 
analysis 
- IL6-T15A 
4.4(1.2-15.7)/0.011 
Haplotype 
analysis:IL6 
GGGA/GGGA or 
GGGA/other 
genotypes 
5.4(1.5-19.2)/0.0033 
 
TNFA 
P=NS 
 
Associated 
with sciatica 
 
 
 
 
 
 
 
Not 
associated 
with sciatica 
19 
1999 Ozawa et al.(22) PCR-RFLP 
Serological 
testing 
HLA class I 
 
 
HLA class II 
NR - Chi-Square 
test 
With Yates’ 
correction 
- HLA-A*33 
P=0.00972 
HLA-B*44 
P=0.003499 
Haplotype 
HLA-A*33-B*44 
P=0.000026 
HLA-A*33-B*44 
-DRB1*1302 
P=0.002089 
Associated 
with PHN 
17 
2012 Ramirez et al. 
(23) 
cDNA sequence Trp101X 
mutation 
- - Genetic 
analysis 
- MPZ Trp101X 
mutation in 
exon 3 coding 
portion of 
MPZ gene 
NA 
2002 Sato et al. (24) PCR-microtitre 
plate 
hybridization 
method 
SNPs in HLA-
A, -B allele, 
HLA-DRB1, 
TNFA, 
NKp30 
NR - Fisher’s exact 
test 
Multiple 
testing 
- HLA-A*3303 
3.27(NA)/0.008 
HLA-B*4403 
3.10(NA)/0.018 
HLA-DRB1*1302 
3.36(NA)/0.019 
Haplotype 
HLA-A*33-B*44 
-DRB1*1302 
P=0.0039 
HLA alleles, 
haplotypes 
associated 
with PHN 
19 
12 
 
2004 Sato-Takeda et 
al. (25) 
PCR-Sequence 
specific primers 
SNPs in 
HLA-A, -B 
allele, HLA-
DRB1 
NR - Chi-Square 
test 
Fisher’s exact 
test 
Multiple 
testing 
- a)PHN vs. ctrl  
A*3303 
3.24/0.0036 
B*4403 
3.07/0.011 
DRB1*1302 
3.45/0.022 
Haplotype 
A*3303- B*4403- 
DRB1*1302 
3.52/0.001 
b) PHN vs. HZ  
A*3303 
4.88/0.014 
B*4403 
4.88/0.026 
DRB1*1302 
2.18/0.063 
Haplotype 
A*3303- B*4403- 
DRB1*1302 
3.34/0.019 
Positive 
association 
between PHN 
and healthy, 
non-PHN HZ 
A*3303- 
B*4403- 
DRB1*1302 
Haplotype – 
risk factor for 
PHN 
19 
2014 Stephens et al. 
(26) 
Illumina Golden 
gate 
rs11674595 
 
IL10 
haplotypes 
rs3024505-
rs3024496-
rs1878672-
rs1518111-
rs1518110-
rs3024491 
Y T 
 
 
 
 
 
GLM logistic 
regression, 
Chi-Square 
test,  
haplotype 
analysis 
PCAs, 
occurrence 
of breast 
pain before 
surgery, 
severity of 
average 
post-
operative 
pain 
IL1 receptor 2 
P<0.0001 
IL10 haplotype A8 
P<0.0001 
Associated 
with PPSP 
25 
2008 Sumiyama et al. 
(27) 
PCR-Sequence 
specific 
oligonucleotide 
probes 
HLA-A, -B 
allele, HLA-
DRB1 
NR - Chi-Square 
test 
With Yates’ 
correction, 
Multiple 
testing 
- PHN+ vs ctrl 
HLA-A*3303 
4.27/0.0007 
HLA-A*02 
0.26/0.001 
HLA-B*4403 
Associated 
with PHN 
20 
13 
 
6.14/0.00005 
DRB1*1302 
4.05/0.007 
PHN+ vs PHN- 
HLA-A*3303 
2.44/0.03 
HLA-A*02 
0.36/0.009 
HLA-B*4403 
3.14/0.006 
DRB1*1302 
2.69/0.03 
2012 Wadley et al. 
(28) 
Illumina 
BeadXpress 
rs10483639, 
rs3783641, 
rs8007267 
Y - Chi-Square 
test with 
multiple 
correction 
Age, gender, 
CD4+ T-cell 
count 
GCH1 
P=NS 
 
 
GCH1 
3-SNP haplotypes 
P=0.05; adjusted P-
value = 0.08 
Individual 
SNPs – not 
associated 
with NP. 
Positive  
results/not 
significant 
after 
correction 
23 
2017 Warner et al. 
(29) 
Illumina 610 k 
array 
rs887797 Y A Chi-square 
test with 
multiple 
correction 
Meta-analysis 
Han Eskin 
random 
effects model 
Age, gender, 
BMI 
Discovery 
PRKCA 
2.00 (1.48-2.70) / 
P=4.29x10-6 
Combined 
2.41 (1.74-3.34) / 
1.65×10-5 
(recessive model) 
Suggestive 
signal; 
associated 
with NP 
27 
CTS, carpal tunnel syndrome; CMT, Charcot Marie tooth syndrome; DFU, diabetic foot ulcer; DPN, distal painful peripheral neuropathy; HIV-SN, human immunodeficiency 
virus – sensory neuropathy; HZ, Herpes Zoster; MS, multiple sclerosis; NP, neuropathic pain; PDPN, painful diabetic peripheral neuropathy; PHN, postherpetic neuralgia; PPSP, 
persistent post-surgical pain; TN, trigeminal neuralgia. CI, confidence interval;  HWE, Hardy-Weinberg equilibrium; OR, odds-ratio, PCR, polymerase chain reaction; PCA, 
principal component analysis; SNP, single nucleotide polymorphisms; STREGA, strengthening of reporting the genetic association studies.  NR, not reported; NS, not significant. 
Grey rows, studies included in the meta-analysis; Non shaded rows, studies not included in the meta-analysis. 
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Table 3. Summary of candidate genes and functional effects of genetic variants reported in this review. 
Gene 
Symbol 
Gene 
Name 
Pathway Function SNP 
( Locus) 
Transcriptional 
Regulation 
(Regulome DB) 
Epigenetic 
regulation 
(ENCODE) 
SNP 
function 
(dbSNP, 
Haploreg) 
NP 
condition 
Studies 
(n) 
 
OPRM1 
 
Mu-type opioid 
receptor 
Neurotransmission,  
Neuroactive ligand-
receptor 
interaction, 
Opioid 
proenkephalin  
G-protein coupled 
receptor activity 
voltage-gated 
calcium channel 
activity 
rs1799971 
(chr6q25.2) 
Minimal protein 
binding  
NRSF, CTBP2 
Lies in DNase 
sensitivity, 
promoter 
histone and 
enhancer; 
hsa-miR-152 
Missense PDPN, 
PPSP 
 
 
 
3 
COMT 
 
Catechol O-
methyltransferase 
Neurotransmission  Metabolize 
catecholamine 
neurotransmitter 
G1947A, 
rs4680 
(chr22q11) 
 
Transcription 
factor binding 
POLR2A / 
NR4A1 
 
Lies in DNase 
sensitivity, 
promoter 
histone and 
enhancer 
Missense Multiple 
aetiologies 
MS, CTS, 
Sciatica 
5 
SCN9A Sodium channel, 
voltage-gated, type 
IX, alpha subunit 
Neurotransmission, 
Neuropathic-pain 
signalling in dorsal 
horn neurons 
Voltage-gated ion 
channel activity 
rs74449889 
(chr2q24.3) 
rs3750904 
rs4369876 
rs12478318 
Minimal binding 
evidence 
hsa-miR-152 Intronic 
 
Missense 
Missense 
Missense 
PDPN 1 
SLC6A4 Solute carrier 
family 6, member 4 
Transporters, 
5HT2 type receptor 
mediated signalling 
pathway, 
Neurotransmission 
Serotonin: sodium 
symporter activity 
neurotransmitter 
transport 
5-HTTLPR short 
rs25531 
(chr17q11.2) 
Minimal binding 
evidence 
Lies in 
promoter  and 
enhancer  
histone  marks 
Missense 
 
1.3kb 5' of 
SLC6A4 
TN 1 
 
 
 
 
CACNG2 Calcium channel, 
voltage-dependent 
gamma subunit 2 
Transmembrane 
AMPAR Regulatory 
Protein Gamma-2 
Neurotransmission, 
Pain signalling 
 
 
Voltage-gated ion 
channel activity 
rs4820242 
(chr22q12.3) 
 
rs2284015 
 
rs2284017 
Minimal binding 
evidence 
SETDB1 
 
Minimal binding 
evidence 
Lies in DNase 
sensitivity and 
enhancer 
histone marks 
Lies in 
promoter 
Intronic PPSP 1 
15 
 
histone marks 
brain tissues 
HLA-A Major 
histocompatibility 
complex, class I, A 
Immune response, 
 
Antigen processing 
and  presentation 
Involved in the 
presentation of 
foreign antigens 
to the immune 
system 
HLA-A*3303 
HLA-A*02 
(chr6p22.1) 
 
NA NA - PHN 
 
5 
HLA-B Major 
histocompatibility 
complex, class I, B-7 
alpha chain 
Immune response, 
Antigen  
presentation 
Involved in the 
presentation of 
foreign antigens 
to the immune 
system 
HLA-B*4403 
allele 
(chr6p21.33) 
 
 
NA NA - PHN 5 
HLA-DQB1 Major 
histocompatibility 
complex, class II, 
DQ beta 1 
Immune response, 
 
Antigen processing 
and  presentation 
Involved in the 
presentation of 
foreign antigens 
to the immune 
system 
HLA-
DQB1*03:02 
allele 
( chr6p21.32) 
NA NA - PPSP 2 
HLA-DRB1 
 
Major 
histocompatibility 
complex, class II, 
DR beta 1 
Immune response, 
 
Peptide antigen 
binding 
Binds peptides 
derived from 
antigens 
HLA-DRB1*04 
HLA-DRB1*13 
( chr6p21.32) 
NA NA - PHN, 
PPSP 
6 
IL6 Interleukin 6 Immune response, 
 
Interleukin 
signalling  
Cytokine activity 
 
rs13306435 
T15A (exon 5) 
(chr7p15.3) 
Transcription 
factor 
 
Likely affect 
binding 
Lies in DNase 
sensitivity, 
foot printing, 
promoter  and 
enhancer  
histone  marks 
Missense Sciatica 1 
IL1R2 
 
Interleukin-1 
receptor, Type II 
Immune response 
 
Protein binding 
Decoy receptor to 
other interleukins 
rs11674595 
(chr2q11.2) 
Minimal binding 
evidence 
Lies in 
promoter  and 
enhancer  
histone  marks 
Intronic PPSP 1 
IL10 Interleukin 10 Immune response, 
 
Interleukin 
signalling  
Negative 
regulation of 
myeloid dendritic 
cell activation 
rs1518110 
(chr1q32.1) 
rs1518111 
rs1878672 
rs3024491 
rs3024496 
Less likely to 
affect binding 
 
 
 
 
Lies in DNase 
sensitivity,  
promoter  and 
enhancer  
histone  marks 
Intronic 
 
Intronic 
Intronic 
Intronic 
3’UTR 
PPSP 1 
16 
 
rs3024498 
rs3024505 
NFKB 
Strongly likely 
to affect binding 
3’UTR 
Intronic 
 
TNF-α Tumour necrosis 
factor alpha 
Immune response Cytokine activity rs1800629 
(chr6p21.33) 
 
Strongly likely 
to affect binding 
and influences 
gene expression 
Lies in DNase 
sensitivity,  
promoter  and 
enhancer  
histone  marks 
312bp 5’ 
TNF 
PPSP 1 
B2M Beta-2-
microglobulin 
Immune response, 
 
Iron metabolism 
Antigen 
processing and 
presentation of 
peptide antigen 
via MHC class I 
rs16966334 
 (chr15q21.1) 
 
rs1901531 
 (chr15q21.1) 
 
Strongly likely 
to affect binding 
 
Minimal binding 
evidence 
Lies in DNase 
sensitivity,  
promoter  and 
enhancer  
histone  marks 
in fetal brain 
Intronic 
 
 
Intronic 
DPN 1 
BMP6 Bone 
morphogenetic 
protein 6 
Immune response Positive regulation 
of neuron 
differentiation 
 
Cytokine activity 
rs270388 
(chr6p24.3) 
 
rs267202 
rs267206 
 
Minimal binding 
evidence 
 
No evidence 
No evidence 
 
Lies in 
enhancer  
histone  marks  
NA 
NA 
Intronic 
 
 
Intronic 
Intronic 
DPN 1 
TF Transferrin Iron metabolism Protein binding rs2718796 
(chr3q22.1) 
rs8177306 
 
Less likely to 
affect binding 
Minimal binding 
evidence 
hsa-miR-152 
 
Lies in DNase 
sensitivity and 
histone marks 
Intronic 
 
Intronic 
DPN 1 
CP Ceruloplasmin 
(ferroxidase) 
Iron metabolism Ferroxidase 
activity /iron 
binding 
rs13072552 
(chr3q24) 
 
rs13075921 
 
rs3816893 
(chr3q25.1) 
 
Minimal binding 
evidence 
 
 
 
No evidence 
Lies in DNase 
sensitivity and 
enhancer 
histone marks 
 
Lies in 
enhancer 
histone marks 
Non-
synonymous 
 
 
Intronic 
Intronic 
DPN 1 
17 
 
TFRC Transferrin 
receptor 
Iron metabolism Chaperone 
binding 
rs480760 
(chr3q29) 
Less likely to 
affect binding 
Lies in DNase 
sensitivity and 
enhancer 
histone marks 
Intronic DPN 1 
ACO1 Aconitase 1, soluble Iron metabolism Iron-responsive 
element binding 
rs7033149 
(chr9p21.1) 
 
 
rs4495514 
 
 
 
 
rs2026739 
 
Likely to affect 
binding and 
linked to gene 
expression 
 
Minimal binding 
evidence 
 
 
 
No evidence 
Lies in DNase 
sensitivity and 
enhancer 
histone marks 
Lies in DNase 
(thymus) 
sensitivity and 
enhancer 
histone marks 
- 
Intronic 
 
 
 
Intronic 
 
 
 
 
Intronic 
 
DPN 1 
FXN Frataxin Iron metabolism Ferroxidase 
activity /iron 
binding 
rs3793451 
(chr9q21.11) 
Minimal binding 
evidence 
Lies in DNase 
sensitivity and 
enhancer 
histone marks; 
hsa-miR-152 
Intronic DPN 1 
GCH1 GTP cyclohydrolase 
1 
 
Metabolism 
Tetrahydrofolate 
biosynthesis, 
Neurotransmission 
 
GTP-dependent 
protein binding 
 
rs752688 
(chr14q22.2) 
 
 
rs3783641 
 
 
 
rs8007201 
Minimal binding 
evidence 
 
 
Likely to affect 
binding  
 
Less likely to 
affect binding 
(EBF1, PU1, 
MEF2A) 
Lies in DNase 
sensitivity and 
enhancer 
histone marks 
Lies in DNase 
sensitivity, 
promoter and 
enhancer 
histone marks 
 
Intronic 
 
 
 
Intronic 
 
 
 
Intronic 
 
PPSP, pain 
due to 
HIV-SN 
2 
SLC11A2 Solute carrier 
family 11 member 
2 
Transporters, 
 
Iron metabolism 
Transmembrane 
transporter 
activity 
rs224446 
(chr12q13.12) 
Minimal binding 
evidence 
Lies in 
enhancer 
histone marks 
 
3’ UTR DPN 1 
18 
 
GFRA2 
 
GDNF family 
receptor alpha 2 
Receptor signalling,  
Immune response 
Gial cell-derived 
neurotrophic 
factor receptor 
activity 
rs17428041 
(chr8p21.3) 
Minimal binding 
evidence 
Lies in 
enhancer 
histone marks 
42kb 5’ of 
GFRA2 
PDPN 1 
HMGB1P46 
 
 
High mobility group 
box 1  
 
 
Immune response Cytokine activity rs6986153 
(chr8q23.1) 
 
- - 190 kb 3’  of 
ANGPT1 
 
PDPN 1 
ZSCAN20 
 
Zinc finger and 
SCAN domain 
containing 20 
Ion binding Transcription 
factor activity 
rs71647933 
(chr1p35.1) 
 
No evidence - Intronic PDPN 1 
PRKCA 
 
Protein kinase C, 
alpha 
Receptor signalling, 
 
Apoptosis signalling 
Signal 
transduction 
Protein binding 
rs887797 
(chr17q24.2) 
Minimal protein 
binding 
EP300 
Lies in DNase 
sensitivity in 
fetal lung, 
promoter 
histone  mark 
in fetal brain 
and enhancer 
Intronic PPSP 1 
TRPA1 
 
 
 
 
Transient receptor 
potential cation 
channel, subfamily 
A, member 1 
Transporters, 
Neurotransmission 
Thermoception rs920829 
(chr8q21.11) 
 
 
 
No evidence 
 
 
 
 
- 
 
 
 
 
Missense 
 
 
 
 
Multiple 
aetiology 
 
 
1 
 
 
 
 
TRPV1 Transient receptor 
potential vanilloid 1 
Ion channel 
activity, 
Neurotransmission 
Thermoception rs222747 
(chr17p13.2) 
rs8065080 
Minimal binding 
evidence 
 
Lies in DNase 
sensitivity 
Missense Multiple 
aetiology 
 
1 
TRPM8 Transient receptor 
potential subfamily 
M member 8 
Ion channel 
activity, 
Neurotransmission 
Ion channel rs13004520 
(chr2q37.1) 
 
rs11562975 
(chr2q37.1) 
 
 
No evidence 
 
 
 
No evidence 
Lies in 
enhancer 
histone marks 
 
Lies in 
enhancer 
histone marks 
Missense 
 
 
 
Synonymous 
Multiple 
aetiology 
 
1 
19 
 
CTS, carpal tunnel syndrome; CMT, Charcot Marie tooth syndrome; DFU, diabetic foot ulcer; DPN, distal painful peripheral neuropathy; HIV-SN, human immunodeficiency 
virus – sensory neuropathy; HZ, Herpes Zoster; MS, multiple sclerosis; NP, neuropathic pain; PDPN, painful diabetic peripheral neuropathy; PHN, postherpetic neuralgia; PPSP, 
persistent post-surgical pain; TN, trigeminal neuralgia. UTR, untranslated region; SNP, single nucleotide polymorphisms; Chr, chromosome; MHC, major histocompatibility 
complex. Genes that are significantly associated with NP are in bolded text. 
  
CYP2D6 Cytochrome P450 
Family 2 Subfamily 
D Member 6 
Drug metabolism Oxidoreductase 
activity, 
Drug binding 
rs3892097 
(chr22q13.2) 
Minimal binding 
evidence 
 
Lies in 
promoter 
histone marks 
liver tissue 
and enhancer 
histone marks 
Splice donor PPSP 1 
MMP1 Matrix 
metallopeptidase 1 
Ion binding Protein 
degradation 
rs1799750 
(chr11q22.3) 
Minimal binding 
evidence 
Protein bound 
CFOS, GATA2 
Lies in DNase 
sensitivity, 
enhancer 
histone marks; 
hsa-miR-22 
1.6 kb 5’ of 
MMP1 
Sciatica 1 
CACNA2D2 Calcium Voltage-
Gated Channel 
Auxiliary Subunit 
Alpha2delta 2 
Transporters Voltage-gated ion 
channel activity 
rs5030977 
(chr3p21.31) 
Affect 
transcription 
binding 
Lies in 
enhancer 
histone marks 
Intronic PPSP 1 
GRIK3 
 
Glutamate 
ionotropic receptor 
kainite type subunit 
3 
Glutamate 
receptor, 
Neuroactive ligand-
receptor 
interaction 
Ion channel 
activity 
rs6691840 
(chr1p34.3) 
Minimal binding 
evidence 
Lies in 
enhancer 
histone marks 
Missense PPSP 1 
BDNF 
 
Brain-derived 
neutrophic factor 
Receptor signalling Nervous system 
development 
rs6265 
(chr11p14.1) 
Minimal binding 
evidence 
Overlaps with 
promoter and 
enhancer 
histone marks 
Missense PPSP 1 
20 
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repeated.  
4 & & 
Table S1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
4 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
4-5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
5 & Table 
1 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
5 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).    Table 2 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
5 
 
Consort/PRIMSA Flowchart
PRISMA 2009 Checklist 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
5 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
5 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
6 & Fig.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
6-7 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  7 & Table 
S4 & S5 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
7-14 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  7-14 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  8-10 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Table 3 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
14-17 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
16-17 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  18 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
18 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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A systematic review and meta-analysis of genetic risk factors for neuropathic pain 
Supplementary tables 
 
Table S1. Search strategy used  
Search terms Combined Keywords using Boolean operators 
Neuropathic pain  
 
“neuropathic pain” OR “neurogenic pain” OR “neuropath* pain” OR “painful peripheral neuropathy” OR “neuralgia 
[MeSH Terms]” OR “nerve pain” OR “pain [MeSH Terms], neuropathic” 
 AND 
Genetic factors “single nucleotide polymorphism*  [MeSH Terms]” OR “genetic polymorphism  [MeSH Terms]” OR “allele” OR “genetic 
variation  [MeSH Terms]” OR “gene variant” OR “mutation  [MeSH Terms]” OR “genes [MeSH Terms]” OR 
“chromosome  [MeSH Terms]” OR “genetic predisposition$ [MeSH Terms]” OR “genetic susceptibility” 
 OR 
Study design “genetic association studies [MeSH Terms]” OR “genome-wide association study [MeSH Terms]” OR “GWAS” OR 
“candidate gene study” OR “twin study” OR “genotype [MeSH Terms]” OR “haplotype [MeSH Terms]” OR 
“heritability*” 
  
Supplementary Materials: figures, tables Click here to download Supplementary Materials: figures, tables
SupplementaryTables revised.docx
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Table S2. Inclusion and Exclusion criteria 
Inclusion criteria Exclusion criteria 
Studies focus on individuals (adults) with neuropathic pain (NP). 
Studies on genetic risk factors for neuropathic pain in humans. 
Genetic studies including genetic association, twin, candidate genes, 
heritability, and family-based studies. 
 
Case-control study design. 
Studies published in English and peer-reviewed journals. 
Studies performed only on animals. 
Case-only studies, review, and case reports. 
Patients with cancer pain, and any pain related conditions that are 
not considered as NP by International Association for the Study of 
Pain (IASP). 
 
Patients with non-neuropathic pain. 
Studies investigating the genetic determinants of pain severity only. 
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Table S3. Full-text study exclusion list 
Author, Year Title Journal Reason for 
exclusion 
Basol et al., 
2013 (1) 
High Association of IL-4 Gene Intron 3 VNTR Polymorphism with Diabetic Peripheral 
Neuropathy 
Journal of Molecular 
Neuroscience 
Not a NP study 
Brasch-
Anderson et 
al., 2011 (2) 
A candidate gene study of serotonergic pathway genes and pain relief during treatment with 
escitalopram in patients with neuropathic pain shows significant association to serotonin 
receptor2C (HTR2C) 
Pharmacogenetics, 
European Journal of 
Clinical Pharmacology  
Not a NP risk 
factor study 
Costigan et al., 
2010 (3) 
Multiple chronic pain states are associated with a common amino acid–changing allele in 
KCNS1 
BRAIN – A Journal of 
Neurology 
Not a NP risk 
factor study 
Dai et al., 2010 
(4) 
Association of catechol-O-methyltransferase genetic variants with outcome in patients 
undergoing surgical treatment for lumbar degenerative disc disease 
The Spine Journal Not a NP risk 
factor study 
Duan et al., 
2010 (5) 
A single-nucleotide polymorphism in SCN9A may decrease postoperative pain sensitivity in 
the general population 
The American Society of 
Anaesthesiologists  
Not a NP risk 
factor study 
Hendry et al., 
2013 (6) 
KCNS1, but not GCH1, is associated with pain intensity in a black southern African population 
with HIV-associated sensory neuropathy: a genetic association study 
Journal of Acquired 
Immunodeficiency 
Syndrome 
Not a NP risk 
factor study 
Hendry et al., 
2016 (7) 
TNF Block Gene Variants Associate With Pain Intensity in Black Southern Africans With HIV-
associated Sensory Neuropathy 
Clinical Journal of Pain Not a NP risk 
factor study 
Hooten et al., 
2013 (8) 
Associations between serotonin transporter gene polymorphisms and heat pain perception in 
adults with chronic pain 
BMC Medical Genetics Not a NP study 
Ide et al., 2014 
(9) 
Haplotypes of P2RX7 gene polymorphisms are associated with both cold pain sensitivity and 
analgesic effect of fentanyl 
Molecular Pain Not a NP study 
Karppinen et 
al., 2008 (10) 
Is the interleukin-6 haplotype a prognostic factor for sciatica? European Journal of 
Pain 
Not a NP risk 
factor study 
Kim et al., 
2010 (11) 
Polymorphic Variation of the Guanosine Triphosphate Cyclohydrolase 1 Gene Predicts 
Outcome in Patients Undergoing Surgical Treatment for Lumbar Degenerative Disc Disease 
SPINE Not a NP risk 
factor study 
Kolesnikov et 
al., 2013 (12) 
Chronic pain after lower abdominal surgery: do catechol-O-methyl transferase/opioid 
receptor μ-1 polymorphisms contribute? 
Molecular Pain Not a NP study 
Olsen et al., 
2012 (13) 
Pain Intensity the First Year after Lumbar Disc Herniation Is Associated with the A118G 
Polymorphism in the Opioid Receptor Mu 1 Gene: Evidence of a Sex and Genotype Interaction 
The Journal of 
Neuroscience  
Not a NP risk 
factor study 
Reimann et al., 
2010 (14) 
Pain perception is altered by a nucleotide polymorphism in SCN9A PNAS Not a NP study 
4 
 
Rooij et al., 
2009 (15) 
HLA-B62 and HLA-DQ8 are associated with Complex Regional Pain Syndrome with fixed 
dystonia 
PAIN 
 
Not a NP study 
Rooijen et al., 
2012 (16) 
Genetic HLA Associations in Complex Regional Pain Syndrome 
With and Without Dystonia 
The Journal of Pain Not a NP study 
Rut et al., 
2009 (17) 
Influence of variation in the catechol-O-methyltransferase gene on the clinical outcome after 
lumbar spine surgery for one-level symptomatic disc disease: a report on 176 cases 
Acta Neurochirurgica Not a NP risk 
factor study 
Schmahl et al., 
2012 (18) 
COMT val158met Polymorphism and Neural Pain Processing PLoS ONE Not a NP study 
Tegeder et al., 
2012 (19) 
GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence Nature Medicine Not a NP risk 
factor study 
Ursu et al., 
2014 (20) 
Gain and loss of function of P2X7 receptors: mechanisms, pharmacology and relevance to 
diabetic neuropathic pain 
Molecular Pain Not a NP risk 
factor study 
Yilmaz et al., 
2014 (21) 
Pain in hereditary neuropathy with liability to pressure palsy: an association with fibromyalgia 
syndrome? 
Muscle and Nerve Not a NP study 
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Table S4. The quality assessment checklist based on the STREGA guidelines 
Item section Quality 
score 
Quality Criteria 
Title & Abstract 1 Study design is clearly stated in title and abstract 
Introduction 
Background 
Objectives 
 
2 
3 
 
Background and rationale 
Aim is clearly reported corresponds to the study question 
Study selection 
Study design 
Setting 
Participants 
Variables 
Data collection 
Case 
Control 
Bias 
Sample size 
Quantitative 
variables 
 
4 
5 
6 
7 
 
8 
9 
10 
11 
12 
 
Eligibility criteria, both inclusion and exclusion criteria are specified 
Study participants recruitment place, duration and method 
Define the study population (participants/non-participants) at each stage, subset from large study 
Demographic, clinical, genetic and other relevant information specific to study 
 
Phenotype measurement/definition, genotype information, quality control metrics, genotyping method 
Phenotype measurement/definition, genotype information, quality control metrics, genotyping method 
Standardized phenotype assessment method, any potential known bias 
Appropriate case / control sample size appropriate to the study design 
Covariates measurement 
 
Statistical methods 13 
14 
15 
16 
 
Appropriate statistical tests 
Genotype information – Hardy Weinberg Equilibrium was considered 
Whether genotypes or haplotypes used for analyses 
Assessed relatedness and population outliers 
 
Results 
Participants 
 
Descriptive data 
 
Outcomes 
 
17 
18 
19 
20 
21 
 
Number of cases passed and failed quality control assessment 
Number of controls passed and failed quality control assessment 
Case: covariates information presented by genotype information 
Control: covariates information presented by genotype information 
Effect size, confidence intervals, P-value presented 
8 
 
 
 
Main results 
 
 
22 
23 
24 
25 
Multiple test correction – appropriate threshold depends on study design 
Statistical model adjustment and other interactions 
Covariate adjusted and unadjusted model results 
Significant results before and after adjusting the model 
Discussion 
Key results 
Limitations 
Interpretation 
 
Generalization 
 
26 
27 
28 
 
29 
 
Whether results supported the study hypothesis or not 
Presented strength and weakness of the study 
Any previous evidence supported the study outcomes, novel result, how it is assessing the risk and clinical 
points 
Replication / validation of the results 
Other information 
Funding 
 
30 
 
Funding source disclosures 
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Table S5. Risk bias assessment of genetic association studies using STREGA guidelines  
Study Title & 
Abstract 
(Max. score 
=1) 
Introduction 
(Max. score 
=2) 
Study 
selection 
(Max. score 
=9) 
Statistical 
methods 
(Max. score 
=4) 
Outcomes 
(Max. score 
=9) 
Discussion 
(Max. score 
=4) 
Funding 
(Max. 
score 
=1) 
Quality score 
(Max. score 
=30) 
Armero et al.  1 2 7 2 3 3 1 19 
Binder et al. 1 2 9 3 2 4 0 21 
Cheng et al. 1 2 8 3 5 3 1 23 
Chung et al. 1 2 7 3 7 4 1 25 
Cui et al. 1 2 9 3 7 3 1 26 
Dominguez et 
al. 
1 2 9 2 6 3 1 24 
Fernandez-de-
las-Penas C et 
al. 
1 2 9 3 5 3 0 23 
Fernandez-de-
las-Penas et al. 
1 2 8 3 6 3 0 23 
Hegarty et al. 1 2 7 2 5 3 1 21 
Jacobsen et al. 1 2 9 3 5 3 0 23 
Jacobsen M et 
al. 
1 2 8 3 6 3 0 23 
Kallianpur et 
al. 
1 2 8 3 7 3 1 25 
Kalliomaki et 
al. 
1 2 9 3 6 4 0 25 
Li et al. 1 2 9 2 7 3 1 25 
Meng et al. 1 2 8 4 7 3 0 25 
Meng et al. 1 2 8 4 7 3 1 26 
Nissenbaum et 
al. 
1 2 7 2 5 2 1 20 
10 
 
Noponen-
Hietala et al. 
1 2 8 2 3 2 1 19 
Ozawa et al. 1 2 5 2 4 2 1 17 
Sato et al. 1 2 7 2 4 2 1 19 
Sato-Takeda et 
al. 
1 2 7 2 4 2 1 19 
Stephens et al. 1 2 7 4 7 3 1 25 
Sumiyama et 
al. 
1 2 6 2 6 3 0 20 
Wadley et al. 1 2 8 4 6 2 0 23 
Warner et al. 1 2 8 4 7 4 1 27 
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Supplementary Figures 
 
 
Supplementary Figure S1. Quality score according to STREGA (Strengthening the reporting of genetic association studies) guidelines for each 
published genetic association studies in neuropathic pain until April 2017. Maximum quality score is 30.
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2. Funnel plot of SE against log OR for OPRM1 variant. 
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Supplementary Figure S3. Funnel plot of SE against log OR for COMT variant. 
14 
 
 
Supplementary Figure S4. Funnel plots of SE against log OR for HLA-DRB1*13. Left, NP (PHN) vs. controls; Right, NP (PHN) vs. participants 
without PHN. 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S5. Funnel plots of SE against log OR for HLA-DRB1*04. 
 
 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S6. Funnel plots of SE against log OR for HLA-DQB1*03. 
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Supplementary Figure S7. Funnel plots of SE against log OR for HLA-A*02. Left, NP vs. controls; Right, NP vs. participants without PHN. 
 
18 
 
 
Supplementary Figure S8. Funnel plots of SE against log OR for HLA-A*33. Left, NP (PHN) vs. controls; Right, NP (PHN) vs. participants without 
PHN. 
19 
 
 
Supplementary Figure S9. Funnel plots of SE against log OR for HLA-B*44. Left, NP (PHN) vs. controls; Right, NP (PHN) vs. participants without 
PHN. 
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the above, the Publisher may assign this Agreement without 
the written consent of the Author (i) to an entity succeeding, 
whether by sale, merger or other corporate reorganization, 
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to substantially all of the Publisher’s assets and business 
activity, or (ii) to a corporation or organization that obtains 
the right to publish the Journal from the Publisher.  The 
Publisher may assign this Agreement to any of its affiliates.  
This Agreement will be binding upon and inure to the 
benefit of the parties hereto and their respective successors 
and permitted assigns. 
b. Counterparts.  This Agreement may be executed in two or 
more counterparts, each of which shall be deemed an 
original, but all of which together shall constitute one and 
the same document.  Facsimile or Portable Document 
Format (PDF) signatures will be deemed original signatures 
for purposes of this Agreement. 
c. Entire Agreement; Amendment.  This Agreement sets forth 
the entire agreement of the parties on the subject hereof 
and supersedes all previous or contemporaneous oral or 
written representations or agreements relating to the rights 
and duties provided herein, and may not be modified or 
amended except by written agreement of the parties. 
d. Force Majeure.  Neither party shall be liable for any 
default or delay on its part in performing any obligation 
under this Agreement if such default or delay is caused by 
natural disaster, accident, war, civil disorder, strike or any 
other cause beyond the reasonable control of such party.  In 
the event that either party is prevented by such an 
occurrence or circumstance for a period of more than ninety 
(90) days from fulfilling its obligations under this Agreement, 
the other party may terminate this Agreement upon thirty 
(30) days’ written notice. 
e. Governing Law.  This Agreement shall be governed in all 
respects according to the laws of the State of New York 
without giving effect to the principles of conflict of law 
thereof. 
f. Headings.  All headings are for reference purposes only 
and shall not affect the meaning or interpretation of any 
provision hereof. 
g. Severability.  If any provision of this Agreement is held to 
be illegal, invalid, or unenforceable under the present or 
future laws, then such provision shall be revised by a court 
of competent jurisdiction to be enforceable if permitted 
under applicable law, and otherwise shall be fully severable.  
In any event, this Agreement shall be construed and 
enforced as if such illegal, invalid, or unenforceable provision 
had never comprised a part of this Agreement, and the 
remaining provisions of this Agreement shall remain in full 
force and effect and shall not be affected by the illegal, 
invalid, or unenforceable provision or by its severance from 
this Agreement. 
h. Status of the Parties.  The parties are independent 
contractors.  Nothing in this Agreement is intended to or 
shall be construed to constitute or establish any agency, 
joint venture, partnership or fiduciary relationship between 
the parties, and neither party has the right or authority to 
bind the other party nor shall either party be responsible for 
the acts or omissions of the other. 
i. Waiver; Amendment.  The waiver by either party of or the 
failure by either party to claim a breach of any provision of 
this Agreement shall not be, or be held to be, a waiver of 
any subsequent breach or affect in any way the further 
effectiveness of any such provision.  No term or condition of 
this Agreement may be waived except by an agreement by 
the parties in writing. 
j. Waiver of Jury Trial.  EACH PARTY HEREBY WAIVES ITS 
RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY 
DISPUTE OR LEGAL PROCEEDING ARISING OUT OF THIS 
AGREEMENT OR THE SUBJECT MATTER HEREOF. 
 
[Signature Page Follows] 
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Schedule A 
This Schedule A must be completed by Author in its entirety.  The Publisher is unable to publish the Work unless 
this Schedule A is completely filled out. 
   
Article Tracking # 
 
   
Article Title (the “Work”) 
 
   
Corresponding Author Name (the “Author”) 
 
   
Copyright Owner’s Name 
 
   
Name of Journal in which Work is to be Published 
 
 
Schedule B 
This Schedule B must be completed by Author in its entirety.  The Publisher is unable to publish the Work unless 
this Schedule B is completely filled out. 
MANDATED FUNDING POLICY DISCLOSURE 
 
1.   Choose a funder from the drop down list. If any of the following are selected please complete Item 2.  
 
 
 
 
NOTE:   If you are a World Health Organization Employee and are required to publish under the Creative Commons CCBY  IGO 
license,  then do not complete  this  form.  Instead, please contact  the Editorial Office  for  the separate WHO Employee  license 
agreement.  
 
2.  If you have selected funding from the above list in 1., please disclose the Open Access option to which the 
Work will be subject. Selecting “Gold Route” will ensure that your work is published under the Creative 
Commons CCBY license. 
□  Gold route 
□  Green route 
NOTE:  If the “Gold” route has been selected, Section 3.b. of the Agreement will apply to the Work, and neither Section 3.a. nor 
Section 3.c. of the Agreement will apply to the Work.  If the “Green” route has been selected, Section 3.c. of the Agreement will 
apply to the Work after an embargo, and neither Section 3.a. nor Section 3.b. of the Agreement will apply to the Work.  
PAIN-D-17-00936
Systematic review and meta-analysis of genetic risk factors for neuropathic pain
Blair H. Smith
Wolters Kluwer
Pain
Wellcome Trust
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3.  □  This Schedule B is inapplicable to the Work. 
NOTE: If author has selected Item 3, Section 3.a. on the Agreement will apply to the Work, and neither Section 3.b. nor Section 
3.c. of the Agreement will apply to the Work.     
GOVERNMENT EMPLOYEES 
4.  □  This work was created in the course of an author’s employment by the United States Government 
 If the Work or a portion of it has been created in the course of any author's employment by the United States 
Government, check the "Government" box at the end of this form. A work prepared by a government employee as 
part of his or her official duties is called a "work of the U.S. Government" and is not subject to copyright. If it is not 
prepared as part of the employee's official duties, it may be subject to copyright.  
If “Government” is chosen, please do not choose a Creative Commons License. The work will be published with 
“Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. 
Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the 
United States Code is not available. As such, copyright does not extend to the contributions of employees of the 
Federal Government.” 
 
NOTE: If author has selected Item 4, Section 3. on the Agreement will not apply to the Work.     
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SIGNATURE PAGE 
The Corresponding Author acknowledges and agrees that the Corresponding Author is entering into, and has 
executed, the Agreement on behalf of the Corresponding Author and each other author named as 
contributing to the Article (each such author, an “Author”, and collectively, the “Authors”). The Corresponding 
Author represents and warrants that the Corresponding Author has obtained permission from each Author to 
enter into the Agreement on behalf of such Author and the Corresponding Author and each Author has read, 
understands, and has agreed to the terms of the Agreement, including, without limitation, the terms 
contained in the Agreement with respect to authorized reuse of the Article.  
 
IN WITNESS WHEREOF, the Author has executed this License, effective as of the Effective Date. 
 
______________________________________________________________________ 
PRINT NAME 
 
______________________________________________________________________ 
SIGNATURE 
 
Important Note: Once you electronically sign this form, you will not be able to make any additional changes to it. 
To electronically sign this form, click the signature field above and provide the information requested in the dialog boxes. 
 
Blair H. Smith
Blair H. Smith Digitally signed by Blair H. Smith Date: 2017.11.25 13:16:08 Z
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